CN113952456A - Epcr通路活化剂在制备抗纤维化剂中的应用 - Google Patents
Epcr通路活化剂在制备抗纤维化剂中的应用 Download PDFInfo
- Publication number
- CN113952456A CN113952456A CN202111512532.XA CN202111512532A CN113952456A CN 113952456 A CN113952456 A CN 113952456A CN 202111512532 A CN202111512532 A CN 202111512532A CN 113952456 A CN113952456 A CN 113952456A
- Authority
- CN
- China
- Prior art keywords
- mice
- fibrosis
- epcr
- nrp1
- hif2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 title claims abstract description 168
- 102000009839 Endothelial Protein C Receptor Human genes 0.000 title claims abstract description 166
- 230000037361 pathway Effects 0.000 title claims abstract description 40
- 239000012190 activator Substances 0.000 title claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000002300 anti-fibrosis Effects 0.000 title abstract description 9
- 239000004215 Carbon black (E152) Substances 0.000 title description 2
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 132
- 230000004761 fibrosis Effects 0.000 claims abstract description 127
- 210000000056 organ Anatomy 0.000 claims abstract description 82
- 230000001737 promoting effect Effects 0.000 claims abstract description 22
- 230000014509 gene expression Effects 0.000 claims description 97
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 76
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 76
- 101100340443 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) infB gene Proteins 0.000 claims description 69
- 101100450707 Schizosaccharomyces pombe (strain 972 / ATCC 24843) hif2 gene Proteins 0.000 claims description 69
- 239000003112 inhibitor Substances 0.000 claims description 53
- 230000000694 effects Effects 0.000 claims description 41
- 230000032683 aging Effects 0.000 claims description 32
- 102000004125 Interleukin-1alpha Human genes 0.000 claims description 30
- 108010082786 Interleukin-1alpha Proteins 0.000 claims description 30
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 29
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims description 28
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 26
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 24
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- 238000011084 recovery Methods 0.000 claims description 19
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 16
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims description 16
- 238000009169 immunotherapy Methods 0.000 claims description 16
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 15
- 230000001172 regenerating effect Effects 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 14
- 206010035664 Pneumonia Diseases 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- HZDKYXAZAPXCKQ-CQSZACIVSA-N 3-[[(3r)-4-(difluoromethyl)-2,2-difluoro-3-hydroxy-1,1-dioxo-3h-1-benzothiophen-5-yl]oxy]-5-fluorobenzonitrile Chemical compound FC(F)C=1C([C@H](C(S2(=O)=O)(F)F)O)=C2C=CC=1OC1=CC(F)=CC(C#N)=C1 HZDKYXAZAPXCKQ-CQSZACIVSA-N 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 230000002068 genetic effect Effects 0.000 claims description 10
- 229960000856 protein c Drugs 0.000 claims description 10
- 101800004937 Protein C Proteins 0.000 claims description 9
- 101800001700 Saposin-D Proteins 0.000 claims description 9
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940126586 small molecule drug Drugs 0.000 claims description 5
- 108700011259 MicroRNAs Proteins 0.000 claims description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 4
- 238000003209 gene knockout Methods 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 238000010362 genome editing Methods 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 3
- 230000017423 tissue regeneration Effects 0.000 claims description 3
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 1
- 230000008929 regeneration Effects 0.000 abstract description 62
- 238000011069 regeneration method Methods 0.000 abstract description 62
- 230000008439 repair process Effects 0.000 abstract description 29
- 230000009286 beneficial effect Effects 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 description 277
- 210000004072 lung Anatomy 0.000 description 125
- 210000002889 endothelial cell Anatomy 0.000 description 101
- 210000004185 liver Anatomy 0.000 description 91
- 210000001772 blood platelet Anatomy 0.000 description 86
- 210000002540 macrophage Anatomy 0.000 description 81
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 51
- 241000699666 Mus <mouse, genus> Species 0.000 description 51
- 210000003734 kidney Anatomy 0.000 description 50
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 49
- 101150051337 NRP1 gene Proteins 0.000 description 49
- 239000007924 injection Substances 0.000 description 49
- 238000002347 injection Methods 0.000 description 49
- 230000006378 damage Effects 0.000 description 36
- 208000027418 Wounds and injury Diseases 0.000 description 33
- 208000014674 injury Diseases 0.000 description 33
- 230000002206 pro-fibrotic effect Effects 0.000 description 33
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 30
- 102100035194 Placenta growth factor Human genes 0.000 description 30
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 30
- 230000008021 deposition Effects 0.000 description 29
- 230000005764 inhibitory process Effects 0.000 description 29
- 238000012753 partial hepatectomy Methods 0.000 description 29
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 29
- 238000011282 treatment Methods 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 27
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 26
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 26
- 210000001616 monocyte Anatomy 0.000 description 24
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 23
- 210000002950 fibroblast Anatomy 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 23
- 230000004913 activation Effects 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 101150097648 Il1a gene Proteins 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 239000003814 drug Substances 0.000 description 20
- 101150077804 TIMP1 gene Proteins 0.000 description 19
- 235000019152 folic acid Nutrition 0.000 description 19
- 239000011724 folic acid Substances 0.000 description 19
- 230000002792 vascular Effects 0.000 description 19
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 18
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 18
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 18
- 230000003511 endothelial effect Effects 0.000 description 18
- 230000003176 fibrotic effect Effects 0.000 description 18
- 229960002591 hydroxyproline Drugs 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 230000008685 targeting Effects 0.000 description 18
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 18
- 101150023500 EPAS1 gene Proteins 0.000 description 17
- 229960002756 azacitidine Drugs 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 102000008186 Collagen Human genes 0.000 description 16
- 108010035532 Collagen Proteins 0.000 description 16
- 229920001436 collagen Polymers 0.000 description 16
- 229960000604 valproic acid Drugs 0.000 description 16
- 230000007115 recruitment Effects 0.000 description 15
- 230000006698 induction Effects 0.000 description 14
- 210000000130 stem cell Anatomy 0.000 description 14
- 108010006654 Bleomycin Proteins 0.000 description 13
- 208000004852 Lung Injury Diseases 0.000 description 13
- 102100028762 Neuropilin-1 Human genes 0.000 description 13
- 229960001561 bleomycin Drugs 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 239000003550 marker Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 12
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 11
- 206010069363 Traumatic lung injury Diseases 0.000 description 11
- 230000002159 abnormal effect Effects 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 229960000304 folic acid Drugs 0.000 description 11
- 230000003394 haemopoietic effect Effects 0.000 description 11
- 238000001543 one-way ANOVA Methods 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 230000003827 upregulation Effects 0.000 description 11
- 244000146510 Pereskia bleo Species 0.000 description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 238000010162 Tukey test Methods 0.000 description 10
- 238000000540 analysis of variance Methods 0.000 description 10
- 230000008672 reprogramming Effects 0.000 description 10
- 238000002271 resection Methods 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 102100026882 Alpha-synuclein Human genes 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 231100000515 lung injury Toxicity 0.000 description 9
- 102000017975 Protein C Human genes 0.000 description 8
- 206010061481 Renal injury Diseases 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 229940014144 folate Drugs 0.000 description 8
- 230000004199 lung function Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 102000003964 Histone deacetylase Human genes 0.000 description 7
- 108090000353 Histone deacetylase Proteins 0.000 description 7
- 102000012355 Integrin beta1 Human genes 0.000 description 7
- 108010022222 Integrin beta1 Proteins 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 108010044426 integrins Proteins 0.000 description 7
- 102000006495 integrins Human genes 0.000 description 7
- 208000037806 kidney injury Diseases 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 6
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 6
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 101150106413 nap1l1 gene Proteins 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000009758 senescence Effects 0.000 description 6
- 238000013424 sirius red staining Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 108010081589 Becaplermin Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 5
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 5
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 210000001043 capillary endothelial cell Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- CDEURGJCGCHYFH-DJLDLDEBSA-N 5-ethynyl-2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-DJLDLDEBSA-N 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 4
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 description 4
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000003067 perivascular macrophage Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 102000016397 Methyltransferase Human genes 0.000 description 3
- 101150116986 THPO gene Proteins 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000009787 cardiac fibrosis Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 3
- 229960002286 clodronic acid Drugs 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229960003699 evans blue Drugs 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000005746 immune checkpoint blockade Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 210000004738 parenchymal cell Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 238000013105 post hoc analysis Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- -1 2,1,3-Benzothiadiazol-4-ylsulfonyl Chemical group 0.000 description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
- CDEURGJCGCHYFH-UHFFFAOYSA-N 5-ethynyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1C(O)C(CO)OC1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004392 Aquaporin 5 Human genes 0.000 description 2
- 108090000976 Aquaporin 5 Proteins 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 102100030024 Endothelial protein C receptor Human genes 0.000 description 2
- 101150097844 F2r gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 2
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 description 2
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 101100153331 Mus musculus Timp1 gene Proteins 0.000 description 2
- 102000016349 Myosin Light Chains Human genes 0.000 description 2
- 108010067385 Myosin Light Chains Proteins 0.000 description 2
- 102000002111 Neuropilin Human genes 0.000 description 2
- 108050009450 Neuropilin Proteins 0.000 description 2
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 102100027548 WW domain-containing transcription regulator protein 1 Human genes 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 108010042591 activated protein C receptor Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 2
- 230000009693 chronic damage Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 231100000784 hepatotoxin Toxicity 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000002074 inflammatory monocyte Anatomy 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 230000019171 interleukin-1 alpha production Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 2
- 229960002169 plerixafor Drugs 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000009719 regenerative response Effects 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 206010067969 Cholestatic liver injury Diseases 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100023721 Ephrin-B2 Human genes 0.000 description 1
- 108010044090 Ephrin-B2 Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 1
- 101000735566 Homo sapiens Protein-arginine deiminase type-4 Proteins 0.000 description 1
- 101000650162 Homo sapiens WW domain-containing transcription regulator protein 1 Proteins 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010040765 Integrin alphaV Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000595924 Mus musculus Placenta growth factor Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 108010070519 PAR-1 Receptor Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 102100038394 Platelet glycoprotein VI Human genes 0.000 description 1
- 101710194982 Platelet glycoprotein VI Proteins 0.000 description 1
- 102100035380 Plexin-D1 Human genes 0.000 description 1
- 101710100518 Plexin-D1 Proteins 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- 102100035731 Protein-arginine deiminase type-4 Human genes 0.000 description 1
- 102000001744 Purinergic P2Y2 Receptors Human genes 0.000 description 1
- 108010029812 Purinergic P2Y2 Receptors Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 102000018227 Semaphorin 3E Human genes 0.000 description 1
- 108050007377 Semaphorin 3E Proteins 0.000 description 1
- 102000013008 Semaphorin-3A Human genes 0.000 description 1
- 108010090319 Semaphorin-3A Proteins 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 101150097457 Vcam1 gene Proteins 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000025164 anoikis Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- VNWKTOKETHGBQD-YPZZEJLDSA-N carbane Chemical compound [10CH4] VNWKTOKETHGBQD-YPZZEJLDSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000010112 hemostatic balance Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000011360 lung alveolus development Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000007040 lung development Effects 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 101150093826 par1 gene Proteins 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000009518 penetrating injury Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 210000000557 podocyte Anatomy 0.000 description 1
- 229940068582 podophyllin Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000006426 vascular sprouting Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及生物医药领域,具体涉及一种EPCR通路活化剂在制备抗纤维化剂中的应用,有助于在一定程度上减轻器官纤维化并促进相应器官的修复和再生。
Description
技术领域
本发明涉及生物医药领域,具体涉及一种EPCR通路活化剂在制备抗纤维化剂中的应用。
背景技术
纤维化(Fibrosis)可以发生于多种器官,是许多常见的慢性炎症性、免疫介导的代谢性疾病的最终病理结果以及这些疾病发病率和死亡率的主要原因。多种有害刺激(包括毒素、传染性病原体、自身免疫反应和机械应激)能够诱导纤维化细胞反应。纤维化会影响身体的所有组织,如果不加以控制,会导致器官衰竭和死亡。
纤维化是组织遭受损伤后,以保护组织器官的相对完整性的修复反应。为了响应组织损伤,源自多种来源的肌成纤维细胞(包括常驻成纤维细胞、间充质细胞、循环成纤维细胞以及其他细胞类型的转分化)可通过重塑细胞外环境来启动伤口愈合反应,以恢复组织完整性并促进实质细胞的替换。通常,当组织愈合时,这种促纤维化程序被关闭。然而,持续的损伤和损害会导致这一过程的失调,导致细胞外基质(ECM)蛋白(包括胶原、层粘连蛋白和纤维连接蛋白)在病理上的过度沉积,并伴随着肌成纤维细胞活性的上调,造成巨噬细胞(和单核细胞)和免疫细胞浸润的慢性炎症环境。而这种“过度沉积”,虽然修复了损伤,但不具备器官实质细胞的结构和功能,反而会引起器官的纤维化和功能障碍。
哺乳动物的器官(例如肝、肺和肾)能够进行代偿性再生来替代受损的组织。然而,大多数哺乳动物的再生能力受到衰老过程的限制。衰老器官中受损的组织常被过度瘢痕(excessive scar)替代,导致纤维化和器官功能障碍。鉴于不同的哺乳动物器官具有不同的自我修复能力,而衰老器官的再生能力似乎受到类似地抑制,并且这些衰老器官在损伤后都容易发生纤维化。
目前对纤维化机制的研究有很多,其中,转化生长因子-β(TGF-β)家族成员被认为在纤维化过程中起主要作用,TGF-β是主要的促纤维化细胞因子。研究认为,许多纤维化疾病都是通过TGF通路介导,促进成纤维细胞分化为肌成纤维细胞,而肌成纤维细胞产生和分泌ECM蛋白增多,造成ECM沉积,致使器官的结构发生变化并硬化。而整合素被认为可以增强来自可溶性促纤维化生长因子(例如TGF-β1)的信号。因此,靶向整合素和靶向TGF-β是热门研究方向。然而,持续地全身性抑制TGF-β1和靶向整合素,具有强烈副作用或存在安全性问题,实际治疗效果不佳;其他治疗纤维化的药物的效果,也并不理想。
长期以来,人们一直认为纤维化不可逆。目前存在的治疗纤维化的药物,往往仅能够在一定程度上抑制纤维化,而难以阻止或逆转纤维化。因此,仍需要开发能够抗纤维化的同时,促进受损器官的再生的新手段。
发明内容
本发明提供了一种EPCR通路活化剂在制备抗纤维化剂中的应用,所述EPCR通路活化剂促进EPCR通路的活性。
进一步地,所述EPCR通路活化剂包括活化蛋白C。
进一步地,所述纤维化包括器官纤维化,所述器官纤维化可选地为与衰老相关的器官纤维化。
进一步地,所述器官纤维化包括肝纤维化、肾纤维化、肺纤维化和心纤维化中的一种或多种,所述肺纤维化可选地为免疫治疗相关肺炎引起的纤维化。
进一步地,所述应用包括减轻受损器官的纤维化程度和/或促进受损器官的再生能力,所述再生能力包括细胞增殖能力、组织修复能力和功能恢复能力中的一种或多种。
进一步地,所述应用包括减轻血小板-巨噬细胞集落的形成;和/或降低血小板IL-1α、SDF1、TIMP1中的一种或多种的表达。
进一步地,所述EPCR通路活化剂用于与NRP1抑制剂和/或HIF2α抑制剂联用制备所述抗纤维化剂,所述NRP1抑制剂和/或HIF2α抑制剂用于促进EPCR的表达。
进一步地,所述NRP1抑制剂包括抑制NRP1蛋白活性的物质、降解NRP1蛋白活性的物质和降低NRP1蛋白水平的基因工具中的一种或多种;所述HIF2α抑制剂包括抑制HIF2α蛋白活性的物质、降解HIF2α蛋白活性的物质和降低HIF2α蛋白水平的基因工具中的一种或多种。
进一步地,所述NRP1抑制剂包括EG00229或其衍生物;所述HIF2α抑制剂包括HIF-2α-IN-1或其衍生物。
进一步地,所述抑制NRP1蛋白活性的物质包括小分子药物和/或抗体;所述抑制HIF2α蛋白活性的物质包括小分子药物和/或抗体。
进一步地,所述降低NRP1蛋白水平的基因工具包括RNA干扰、microRNA、基因编辑和基因敲除中的一种或多种;所述降低HIF2α蛋白水平的基因工具包括RNA干扰、microRNA、基因编辑和基因敲除中的一种或多种。
另一方面,本发明还提供一种用于评估器官纤维化的标记物组,其特征在于,所述标记物组包括NRP1、HIF2α和EPCR中的一种或多种;所述标记物组的表达量可用于评估器官纤维化程度和/或器官功能受损情况。
进一步地,所述标记物组进一步包括PlGF、SDF1、IL-1α、CXCR4、TIMP中的一种或多种。
进一步地,所述器官纤维化包括肝纤维化、肾纤维化、肺纤维化和心纤维化中的一种或多种。
进一步地,所述器官纤维化为与衰老相关的器官纤维化。
另一方面,本发明还提供一种用于评估器官纤维化的试剂盒,其特征在于,包括一种标记物组,所述标记物组包括NRP1、HIF2α和EPCR中的一种或多种。
进一步地,所述标记物组进一步包括PlGF、SDF1、IL-1α、CXCR4、TIMP中的一种或多种。
进一步地,所述试剂盒用于检测生物样本中所述标记物的基因表达水平,所述生物样本包括血液样本、血清样本、血浆样本、组织样本、器官样本和细胞样本中的一种或多种。
进一步地,所述器官纤维化包括肝纤维化、肾纤维化、肺纤维化和心纤维化中的一种或多种。
进一步地,所述器官纤维化为与衰老相关的器官纤维化。
有益技术效果
本发明提供EPCR通路活化剂在制备抗纤维化剂中的应用。本发明技术方案所靶向的EPCR(内皮细胞蛋白C受体),是内皮细胞特异性表达的位于细胞膜的跨膜糖蛋白,而血管内皮细胞分布在几乎所有的器官中,在生物体内数量庞大。本发明实验人员经一系列实验发现,EPCR通路的抑制是器官再生向纤维化转变的一个重要节点。本发明实验人员利用血管内皮细胞、血小板以及巨噬细胞在内的多细胞类型之间相互作用,干预EPCR抑制的上游(即抑制NRP1和/或HIF2α)有助于上调EPCR,进而对EPCR抑制的下游(即IL-1α、TIMP1等)进行抑制;同理,还可以直接干预EPCR或在直接干预EPCR的同时干预EPCR抑制的上游,在一定程度上促进无纤维化的器官修复。现有技术往往仅针对单一靶点,治疗效果不佳;而直接靶向整合素或靶向TGF-β,存在安全性等问题。而本发明提供的EPCR通路活化剂在制备抗纤维化剂中的应用,结合循环系统易于干预(readily accessible)这一特点,能够调节多种细胞类型(即循环系统中的血管内皮细胞、血小板、巨噬细胞)产生的多种分子(例如EPCR、IL-1α、TIMP1等),以多角度来调节受损器官的纤维化,并促进受损细胞的再生。本发明的技术方案能够抑制促纤维化的血小板IL-1α和巨噬细胞TIMP1,而巨噬细胞TIMP1又经证明,其能够通过整合素刺激成纤维细胞的活化(也可以理解为,整合素为EPCR的下游)。因此,本发明技术方案在抗纤维化方面的治疗效果明显,具体体现为:降低IL-1α、SDF1、TIMP1的表达并减轻促纤维化的“血小板-巨噬细胞”集落,抑制内皮细胞中的Rho通路激活、减少炎性单核细胞的沉积,以减轻受损器官纤维化程度并促进再生(包括受损器官的实质细胞增殖、组织修复、功能恢复等)、促进受损器官的无纤维化(fibrosis-free)修复等。需要强调的是,本发明的技术方案还能通过降低巨噬细胞TIMP1表达等方式,进一步抑制成纤维细胞的活化。上述治疗效果在肺、肝、肾的再生和纤维化模型及其相应衰老模型中均得到了验证。
长期以来,人们一直认为纤维化不可逆。现有技术往往仅能够在一定程度上抑制纤维化,而难以“逆转纤维化”。本发明通过靶向EPCR(或与NRP1抑制剂和/或HIF2α抑制剂联用,进而靶向EPCR),调控EPCR的表达,进而影响循环系统中血小板IL1α和巨噬细胞TIMP1的表达,即正常化血小板-巨噬细胞-血管内皮细胞之间的异常相互作用,在一定程度上抑制纤维化并恢复受损器官的再生能力,实现“逆转纤维化”(即受损器官的无纤维化修复,使受损器官从纤维化向再生转变)的效果。此外,本发明提供的应用,还可以在一定程度上缓解免疫治疗诱导的肺炎(Immunotherapy-induced pneumonitis)。
综上所述,本发明技术方案提供的EPCR通路活化剂在制备抗纤维化剂中的应用,有助于在一定程度上系统地缓解或治疗,甚至逆转器官纤维化。
本发明涉及的主要英文缩写汇总
EPCR:Endothelial protein C receptor,内皮蛋白C受体;HIF2α:Hypoxia-inducible-factor2α,缺氧诱导因子2α;NRP1:Neuropilin1,神经纤毛蛋白1;TIMP1:Tissueinhibitor of metalloproteinases1,金属蛋白酶组织抑制剂1;IL-1α:Interleukin-1α,白介素1α;ECs:Endothelial cells,内皮细胞;PCECs:Pulmonary capillary endothelialcells,肺毛细血管内皮细胞;PlGF:Placental growth factor,胎盘生长因子;SDF1:stromal-derived factor 1,基质衍生因子1;HDAC:Histone deacetylase,组蛋白脱乙酰基酶;VPA:Valproic acid,丙戊酸;DNMT:DNA methyltransferase,DNA甲基转移酶;AZA:5-azacitidine,5-氮杂胞苷;PNX:Pheumonectomy,肺切除手术;PH:Partial hepatectomy,肝部分切除术;I/R:Ischemia-reperfusion,缺血再灌注。
如本文所使用,“促进”是指所描述对象在既有水平的进一步提高,所述既有水平包括数量水平、表达水平、功能水平、能力水平中的一种或多种。
如本文所使用,“逆转纤维化”是指将呈纤维化状态的器官向再生方向转变,包括降低纤维化的水平、降低纤维化引起的症状的严重程度、增强再生能力。
如本文所使用,“促进EPCR通路的活性”是指增强EPCR信号和/或增加EPCR的表达水平,使得EPCR与其下游分子产生作用。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作一简单地介绍。显而易见地,下面描述中的附图是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动性的前提下,还可以根据这些附图获得其它的附图。
图1为肺中衰老的内皮细胞中NRP1的异常诱导抑制再生以促进纤维化的实验图;
图2为衰老的肝和肾的内皮细胞中重编程的EPCR信号抑制再生并刺激纤维化的实验图;
图3为老年小鼠器官中受内皮细胞NRP1抑制的EPCR上调基质衍生因子1(SDF1)以募集促纤维化的巨噬细胞的实验图;
图4为巨噬细胞/单核细胞来源的金属蛋白酶组织抑制剂促进成纤维细胞的活化并增强纤维化的实验图;
图5为血小板源性IL-1α与巨噬细胞相互作用以形成促纤维化的造血集落的实验图;
图6为内皮细胞NRP1或血小板IL-1α的遗传靶向,减少博来霉素损伤后衰老的肺的纤维化的实验图;
图7为内皮细胞HIF2α或血小板IL-1α的阻断减少衰老器官中免疫治疗诱导的肺炎、肝纤维化和肾纤维化的实验图;
图8为肺切除术(PNX)后衰老小鼠肺的内皮细胞中受损的肺再生、神经纤毛蛋白1(NRP1)-HIF2α通路的异常诱导和受抑制的内皮蛋白C受体(EPCR)的实验图;
图9为NRP1-HIF2α通路的活化,降低衰老的肝和肾EC中EPCR的表达的实验图;
图10为损伤后老年器官中内皮细胞NRP1募集促纤维化的巨噬细胞的实验图;
图11为所述小鼠组中巨噬细胞的表型的实验图;
图12为年轻小鼠中EPCR中和抗体与巨噬细胞TIMP1对肺再生和纤维化的影响的实验图;
图13为内皮细胞中异常的NRP1信号,通过募集表达TIMP1的促纤维化的巨噬细胞,促进肺纤维化和衰老的实验图;
图14为损伤后的老年肝和肾中,内皮细胞的异常的NRP1-HIF2α信号及TIMP1的促纤维化功能的实验图;
图15为APC-EPCR通路在促进无纤维化器官修复中的作用模型的示意图;
图16为小鼠反复吸入盐酸后,内皮细胞中EPCR的抑制和NRP1的诱导与肺纤维化有关的实验图;
图17为Nrp1的阻断恢复内皮微环境中EPCR的表达,其与APC协同作用以促进酸损伤后无纤维化肺修复的实验图;
图18为靶向Nrp1/HIF2α和EPCR通路,减轻肝和肾的纤维化的实验图;
图19为NRP1-HIF2α抑制和APC治疗,促进长期损伤后的肝脏和肾脏的适应性修复的实验图。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述。显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
需要说明的是,在本文中,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者装置不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者装置所固有的要素。在没有更多限制的情况下,由语句“包括一个……”限定的要素,并不排除在包括该要素的过程、方法、物品或者装置中还存在另外的相同要素。
如在本说明书中使用的,术语“大约”,典型地表示为所述值的+/-5%,更典型的是所述值的+/-4%,更典型的是所述值的+/-3%,更典型的是所述值的+/-2%,甚至更典型的是所述值的+/-1%,甚至更典型的是所述值的+/-0.5%。
在本说明书中,某些实施方式可能以一种处于某个范围的格式公开。应该理解,这种“处于某个范围”的描述仅仅是为了方便和简洁,且不应该被解释为对所公开范围的僵化限制。因此,范围的描述应该被认为是已经具体地公开了所有可能的子范围以及在此范围内的独立数字值。例如,范围1~6的描述应该被看作已经具体地公开了子范围如从1到3,从1到4,从1到5,从2到4,从2到6,从3到6等,以及此范围内的单独数字,例如1,2,3,4,5和6。无论该范围的广度如何,均适用以上规则。
附图详细说明
图1:(A)表明检测肺切除手术(PNX)后年轻小鼠与老年小鼠肺泡再生策略的方案的示意图。(B-C)所示年龄的小鼠的肺泡上皮结构的恢复(B)以及羟脯氨酸量(C)。进行I型肺泡上皮细胞(AEC)标记物水通道蛋白5(AQP5)和平足蛋白(PDPN)的免疫染色和天狼星红染色。20月龄小鼠(定义为“老年”小鼠)显示出更低程度的肺泡再生和更高程度的纤维化;每组n=8只小鼠。比例尺皆为50μm(除非另有指明)。(D)PNX后,小鼠中血小板和巨噬细胞的肺部沉积。血小板标记物CD41、巨噬细胞标记物F4/80和血管内皮细胞标记物VE-钙黏蛋白共染色。老年小鼠肺中,血小板与巨噬细胞形成细胞集落(箭头所示)。(E)PNX后,2月龄以及20月龄“老年”小鼠的肺毛细血管内皮细胞(PCECs)中改变的旁分泌/血管分泌基因的热图。(F)PNX后,老年对照组小鼠以及诱导性EC特异性删除Nrp1的小鼠(Nrp1iΔEC/iΔEC)中内皮蛋白C受体(EPCR)和缺氧诱导因子2α(HIF2α)的表达。(G)与对照组小鼠相比,PNX后的老年Nrp1iΔEC/iΔEC小鼠中“血小板-巨噬细胞”集落的形成减少,这种现象被EPCR中和抗体1560逆转。(H)在所示年龄的Nrp1iΔEC/iΔEC小鼠以及Nrp1+/+小鼠中再生和纤维化应答。评估PNX后II型肺泡上皮祖细胞的增殖。5-乙炔基-2'-脱氧尿苷(EDU)掺入(incorporation)与表面活性蛋白C(surfactant protein C,SPC)共染色。用β-半乳糖苷酶(β-Gal)活性染色检测衰老(senescence)。LY6g的免疫染色评估中性粒细胞的积聚(accumulation)。通过注射高分子量右旋糖酐(F)检测血管通透性。(I)在衰老内皮细胞中,NRP1的上调刺激HIF2α并抑制抗炎症且抗血栓的EPCR。EPCR的抑制活化血小板和巨噬细胞以形成促纤维化的造血集落。数据表示为平均值±平均值标准误差(SEM)。统计学差异由单因素方差分析(ANOVA)及随后作为事后分析的Tukey检验确定。*P<0.05。
图2:(A)检测PH后的年轻小鼠和老年小鼠的肝再生。(B-C)评估造血集落的沉积(B)以及内皮细胞中所示基因的转录水平(C)(每组n=8-9只小鼠)。(D)PH后,所述小鼠组的肝内皮细胞中HIF2α蛋白。HIF2α的表达由与内皮细胞核标记物ETS相关基因(ERG)(E)共染色检测。(E-I)PH后,老年Nrp1iΔEC/iΔEC小鼠以及对照组小鼠的肝脏中“血小板-巨噬细胞”集落的积聚、肝细胞增殖以及纤维化。进行天狼星红染色(E)。检测EDU掺入来评估肝细胞增殖(F)。所示小鼠中天冬氨酸转氨酶(AST)的血清浓度(G)(每组n=7只小鼠),血小板-巨噬细胞聚集体(aggregate)的分布(H),和血浆胆红素浓度(I)(每组n=9只小鼠)。(J)检测缺血再灌注(I/R)后年轻小鼠和老年小鼠的肾修复。(K-N)I/R后2月龄和20月龄“老年”小鼠在肾内皮细胞中“血小板-巨噬细胞”集落的形成(K)、所示基因的转录水平(L和M)和EPCR和NRP1蛋白的表达(N)(每组n=6只小鼠)。(O-R)I/R后老年Nrp1iΔEC/iΔEC小鼠以及对照组小鼠中造血集落的分布、肾纤维化、细胞增殖和肾功能的恢复(O)。评估EDU掺入来测量肾细胞的增殖(P)。共染色血小板、巨噬细胞和内皮细胞于肾载玻片(Q),测定所述小鼠的血清肌酐(R)(每组n=9只小鼠)。数据表示为平均值±SEM。统计学差异以单因素方差分析(ANOVA)及随后的Tukey事后检验确定。
图3:(A)SDF1报告小鼠或缺乏内皮细胞NRP1的报告小鼠的PCECs中SDF1的表达。在肺切片中SDF1表达(红色荧光蛋白)与VE-钙黏蛋白共染色。(B)PNX后的老年对照组小鼠以及EC特异性HIF2α敲除(Hif2aiΔEC/iΔEC)小鼠的PCECs中所示基因的表达(每组n=6只小鼠)。*P<0.05,与老年对照组相对;#P<0.05,与用1560抗体处理的老年Hif2aiΔEC/iΔEC小鼠相比较。(C-D)所示小鼠中CXCR4+巨噬细胞的募集以及II型肺泡祖细胞的增殖。巨噬细胞的定量显示为(C)(每组n=6只小鼠)。CXCR4与F4/80共染色并且测量EDU掺入来评估细胞增殖(每组n=6只小鼠)(D)。(E)所示小鼠中肺部巨噬细胞中细胞因子的表达(每组n=6只动物)。(F-H)小鼠成纤维细胞或星状细胞中,Smad2磷酸化(p-Smad2)和α-SMA蛋白表达。用shRNA(sh整合素β1)沉默成纤维细胞中的整合素β1。代表性印迹图像显示为(F),并且蛋白定量显示为(G)和(H)(每组n=5个单个样本)。数据表示为平均值±SEM。统计学差异以单因素方差分析(ANOVA)及随后的Tukey事后检验评估。
图4:(A)PNX后缺乏Timp1(Timp1-/-)老年小鼠以及年轻和老年对照组小鼠的肺泡上皮细胞的恢复以及胶原沉积。(B)所述小鼠的巨噬细胞中Timp1的表达。老年小鼠还用CXCR4拮抗剂AMD3100或者赋形剂(vehicle)(每组n=5只小鼠)。(C)描述检验巨噬细胞TIMP1促进衰老相关的纤维化的作用的方法的方案的示意图。(D-F)有或没有转移所述单核细胞的年轻和老年的经肺切除的小鼠中,肺部功能的恢复(D)、动脉氧合(E)和羟脯氨酸量(F)的恢复(每组n=9只小鼠)。N/A表示未转移单核细胞。(G-H)所示小鼠组的肺(G)以及肝脏和肾脏(H)的天狼星红染色。(I-J)经所示处理的小鼠中血浆胆红素(I)和血清肌酐(J)的浓度(每组n=9只小鼠)。N/A表示未转移单核细胞。(K)在肺、肝和肾损伤后,老年内皮细胞中NRP1受到诱导以上调HIF2α并且抑制EPCR的诱导。形成表达SDF1的内皮微环境,以增强CXCR4+TIMP1高表达的巨噬细胞的沉积。这些巨噬细胞可能有助于“血小板-巨噬细胞”集落的促纤维化功能,在衰老的肺、肝和肾中将再生性应答逆转成纤维化。统计学差异以单因素方差分析(ANOVA)及随后作为事后分析的Tukey检验确定。数据表示为平均值±SEM。
图5:(A-B)血小板特异性删除IL-1α小鼠(Il1aΔPlt/ΔPlt)。Floxed IL-1α(Il1aloxP /loxP)小鼠与表达血小板特异性Pf4-cre小鼠杂交,产生Il1aΔPlt/ΔPlt小鼠(A)。比较所述组在PNX、PH或肾I/R后,TIMP1的表达以及“血小板-巨噬细胞”集落的形成(B)。(C-E)年轻对照组以及Il1aΔPlt/ΔPlt小鼠在所示处理后,“血小板-巨噬细胞”集落在肺(C)、肝(D)、肾(E)的沉积(每组n=4只小鼠)。(F-G)检测(F)和定量(G)所示小鼠组中TIMP蛋白的表达(每组n=4只小鼠)。(H)检验衰老的器官中血小板源性IL-1α对纤维化的影响的策略。Il1a+/+和Il1a-/-血小板注入到老年Thpo-/-小鼠中。评估受试小鼠中TIMP1的表达和胶原沉积。(I-K)在受试小鼠的衰老器官中,Il1a-/-(而不是Il1a+/+)抑制TIMP1的表达(I),并减少再生到纤维化的转变。定量不同组的TIMP1表达(每组n=4只小鼠)。(L)衰老器官中重编程的内皮细胞EPCR信号导致血小板活化。由血小板提供的IL-1α刺激募集的巨噬细胞,促进促纤维化的“血小板-巨噬细胞”集落的形成,并且在损伤后抑制再生至促进纤维化。数据表示为平均值±SEM。统计学差异以单因素方差分析(ANOVA)及随后作为事后分析的Tukey检验。
图6:(A)通过向老年小鼠气管内注射博来霉素(Bleo)来诱导肺损伤和纤维化的实验流程。(B)博来霉素损伤后,老年小鼠肺的PlGF蛋白表达(每组n=6只小鼠)。(C)博来霉素损伤后,所示小鼠组中HIF2α和EPCR的蛋白表达。(D)博来霉素损伤后,肺的肺泡上皮细胞的分布、SMA的表达、CXCR4+巨噬细胞的积聚和衰老相关的β-半乳糖苷酶。(E-F)检测博来霉素损伤后的所示小鼠的I型胶原的蛋白水平(E)以及肺部功能的恢复(F)(每组n=10只小鼠)。(G)博来霉素损伤后,过继转移血小板和单核细胞到小鼠的示意图。(H-I)所述小鼠中“血小板-巨噬细胞”聚集体的沉积(H)及肺TIMP1的表达(I)。博来霉素损伤的小鼠中,血小板Il1a-/-的移植抑制了造血血管集落(hematopoietic-vascular rosette)的形成以及TIMP1的表达(每组n=4只小鼠)。(J-K)博来霉素损伤后,移植所示单核细胞的老年受试小鼠进行羟脯氨酸量的测量(J)和天狼星红染色(K)。N/A表示未转移单核细胞。(每组n=6只小鼠)。(L)衰老内皮细胞中抗血栓的EPCR信号的抑制,导致血小板来源的IL-1α的产生,其与表达促纤维化的TIMP1的血管周围的巨噬细胞相互作用。数据表示为平均值±SEM,统计学差异以单因素方差分析(ANOVA)及随后的Tukey事后检验确定。
图7:(A)免疫治疗诱导的肺炎的小鼠模型。用抗程序性细胞死亡蛋白1(PD1)抗体和幅射处理年轻和老年小鼠。测量动物发病率以及肺纤维化。(B-C)所示小鼠的肺胶原沉积(B)以及动物生存率(C)(每组n=10只小鼠)。(D-F)所示组中肺胶原沉积(D)、支气管肺泡灌洗液(bronchioalveolar lavage fluid,BALF)中IL-1α的浓度(E)、和动物生存率(F)。老年小鼠被移植血小板并接受所示处理(每组n=8-10只小鼠)。(G)检测免疫治疗后肺中血小板Il1α对纤维化的影响和肿瘤进展的方法。向老年小鼠注射lewis肺癌(LLC)细胞、移植所示血小板,并接受所述处理。(H-I)所示处理后,评估肺肿瘤负荷、胶原沉积(H)和肺羟脯氨酸量(I)(每组n=10-12只小鼠)。(J)已移植血小板的小鼠的存活曲线(每组n=10只小鼠)。(K)通过分别注射四氯化碳(CCl4)和注射叶酸诱导出的肝和肾纤维化。(L)CCl4损伤后小鼠肝脏的PlGF蛋白量(每组n=8只小鼠)。(M)所述小鼠的肝中I型胶原的蛋白量。(N)所示小鼠组中肝、肾的天狼星红染色。(O)CCl4或叶酸处理后,移植所示血小板的老年受试小鼠中造血集落的形成。(P)CCl4损伤后,注射所述单核细胞的老年受试小鼠的肝羟脯氨酸(每组n=6只小鼠)。数据表示为平均值±SEM,统计学差异以单因素方差分析(ANOVA)及随后的Tukey事后检验确定。
图8:是对图1实验的补充,与其相关。(A-C)PNX后的所示年龄小鼠的肺部功能的恢复、胶原和“血小板-巨噬细胞”集落的沉积。测量血液氧合和吸气量。进行天狼星红染色和I型胶原免疫印迹,并检测“血小板-巨噬细胞”聚集体的形成。20月龄(老年)小鼠展示出更低的肺泡再生和更高的纤维化。在所有附图中,点图中的每个点表示来自单个动物的数据。Sh表示假手术组;PNX表示肺切除术组。(D)与2月龄小鼠肺相比,PNX后的衰老的小鼠肺的肺毛细血管内皮细胞(PCECs)中,改变的旁分泌相关基因。每组N=5-6只。图8中比例尺为50μm。**,与老年组相对,P<0.05。统计学差异由单因素方差分析(ANOVA)及随后的Tukey事后检验确定。(E)比较老年对照组小鼠与诱导性内皮细胞特异性删除Nrp1(Nrp1iΔEC/iΔEC)小鼠之间,肺和肝内皮细胞中神经纤毛蛋白1的表达。(F)PNX后,对照组小鼠与老年Nrp1iΔEC/iΔEC小鼠中EPCR和HIF2α的表达。分别比较3月龄小鼠(年轻)与20月龄小鼠(老年)。每组N=5只小鼠。(G)与对照组小鼠相比,老年Nrp1iΔEC/iΔEC小鼠的“血小板-巨噬细胞”集落的形成减少,而这种现象被EPCR中和抗体1560逆转。每组N=6只小鼠。(H)所示小鼠组肺中羟脯氨酸量、β-半乳糖苷酶(β-gal)活性以及p16的表达。*P<0.05,统计学差异由单因素方差分析(ANOVA)及随后的Tukey事后检验确定。(I)PNX后,所示小鼠组的血管生长和灌注、血管周围中性粒细胞的分布、血管渗漏(vascular leak)和肺II型肺泡祖细胞的增殖。向小鼠静脉注射B4同工凝集素(B4-isolectin)和伊文思蓝(Evans blue)。对肺中同工凝集素+血管和残留的伊文思蓝定量。比例尺为50μm。
图9:是对图2实验的补充,与其相关。(A)检测部分肝切除术(PH)后年轻和老年小鼠的肝再生。测量所示组中肝中羟脯氨酸量。(B-C)PH或肾缺血再灌注(I/R)后,所示组的血管周围中性粒细胞的分布。(D)假手术(sham)以及PNX后,年轻Nrp1+/+、老年Nrp1+/+,以及老年Nrp1iΔEC/iΔEC小鼠的肺ECs中EPCR蛋白水平。EPCR蛋白定量以柱状图显示。每组N=4-5只小鼠。(E)PNX和PH后,所示小鼠组的肺和肝中PlGF蛋白量。每组N=4只小鼠。(F)注射PlGF和等量的血小板源性生长因子BB(PDGF)、肝细胞生长因子(HGF)、血管内皮细胞生长因子165(VEGF)、肿瘤生长因子β1(TGFβ1)后,所示小鼠组肺内皮细胞的EPCR蛋白水平。N=4。(G)3月龄对照组、Nrp1iΔEC/iΔEC小鼠以及内皮细胞特异性诱导性敲除HIF2α(Hif2aiΔEC/iΔEC)小鼠的肺ECs中PlGF介导的EPCR蛋白的抑制。每组N=4。(H)所示小鼠的肝ECs中通过PlGF的EPCR抑制。每组N=4只。(I)PNX、PH或肾I/R后,所示小鼠的内皮细胞中NRP1蛋白的表达。用组蛋白脱乙酰基酶(HDAC)抑制剂(VPA)、DNA甲基转移酶(DNMT)抑制剂氮杂胞苷(AZA)或VPA与AZA的联合注射(VPA+AZA)处理老年小鼠。veh表示赋形剂。N=5。(J)所示小鼠组中PlGF的蛋白量。veh表示赋形剂;每组N=5-6只小鼠。(K)在老年小鼠器官中,损伤后表观遗传上调的PlGF-NRP1通路,抑制内皮细胞EPCR的诱导。
图10:对图3实验的补充,与其相关。(A)PNX后,老年Nrp1iΔEC/iΔEC小鼠以及对照组小鼠的肺毛细血管内皮细胞中所示基因的表达。N=5。(B)PNX后,SDF1在所示小鼠的肺中成纤维细胞中的转录表达。N=6。(C-D)PNX后,小鼠肺中CXCR4+巨噬细胞的募集。通过CXCR4与F4/80的共染色,检测表达CXCR4的巨噬细胞。N=6。(E)所述小鼠组中肺细胞增殖。(F)PH后,所示小鼠肝中的羟脯氨酸量。统计学差异由单因素方差分析(ANOVA)及随后的Tukey事后检验确定。(G)老年Nrp1iΔEC/iΔEC小鼠以及年轻和老年对照组小鼠的内皮细胞中所示基因的表达。N=5。*P<0.05,与老年Nrp1+/+组相对;#P<0.05,与用1560处理的老年Nrp1iΔEC/iΔEC小鼠相比。(H)所示小鼠的CXCR4+巨噬细胞的数量。PH和肾I/R后的肝脏和肾脏切片,用于CXCR4和F4/80染色。N=5。(I)正常化老年PCECs中EPCR信号,阻断血管微环境的促纤维化功能。PNX后,老年小鼠PCECs中NRP1-HIF2α信号,抑制EPCR以诱导SDF1表达。在老年、经肺切除的肺中PCECs中SDF1的表达,募集促纤维化的TIMP1+血管周围巨噬细胞,以阻碍肺泡再生,并且促进纤维化。
图11:是对图4实验的补充,与其相关。(A)单个标记物在所述巨噬细胞中的表达。从PNX、PH或肾脏I/R后的3月龄(年轻)和老年小鼠的肺、肝和肾中分离出巨噬细胞。(B)来自衰老器官的老年对照组以及Hif2aiΔEC/iΔEC小鼠的巨噬细胞中所示基因的表达。(C)所示小鼠组的肺、肝和肾中F4/80与CD86的共染色。比例尺为50μm。
图12:是对图5实验的补充,与其相关。(A-B)向PNX后的3月龄小鼠(年轻)注射EPCR中和抗体1560。检测I型肺泡上皮细胞的恢复以及血液氧合。(C-D)PNX以及注射1560后,年轻的肺的胶原沉积以及羟脯氨酸水平。年轻小鼠为3月龄。N=6,比例尺为50μm。(E)相对于用同型匹配的(isotype-matched)IgG处理的小鼠,注射EPCR抗体后的年轻小鼠肺中“血小板-巨噬细胞”聚集体的增加的积聚。(F)检测EPCR阻断后巨噬细胞TIMP1对肺纤维化的作用的策略。注射EPCR抗体后,从Timp1-无效(Timp1-/-)以及对照组Timp1+/+小鼠中分离出单核细胞,并转移到年轻小鼠中。(G-H)EPCR抗体的阻断后,Timp1-/-(而不是Timp1+/+)单核细胞的移植,减少了肺纤维化的增加。分析小鼠肺中胶原沉积和羟脯氨酸量。N=5,比例尺为50μm。
图13:是对图6实验的补充,与其相关。(A)所示基因型的小鼠组中,CXCR4+巨噬细胞的募集及气管内注射博来霉素(Bleo)后的处理。(B-C)Bleo损伤后,所示小鼠组中β-半乳糖苷酶和p16的表达水平。每组N=5-6只小鼠。(D-E)Bleo损伤后,老年Timp1-/-小鼠以及年轻和老年Timp1+/+小鼠的羟脯氨酸量、肺泡上皮细胞再生以及I型胶原的沉积。年轻小鼠为3月龄小鼠,比例尺为50μm。
图14:是对图7实验的补充,与其相关。(A)CCl4或叶酸损伤后,所示基因型的小鼠组的肝和肾中HIF2α和EPCR的表达。(B)CCl4损伤后,所示小鼠组的肝中羟脯氨酸量。(C)CCl4或者叶酸处理后,已移植Il1a-/-或者Il1a+/+血小板的老年宿主/受试Thpo-/-小鼠中的促纤维化的TIMP1的表达。在肝或者肾损伤后,已转移Il1a-/-血小板的Thpo-/-小鼠中,TIMP1在肝或肾中的表达不受EPCR抗体的影响,这意味着血小板产生的Il1a是EPCR抑制的下游。(D)CCl4或叶酸处理后,已移植Timp1-/-或Timp1+/+单核细胞的老年WT小鼠中胶原沉积。(E)胆管结扎(BDL)(一种胆汁淤积性肝损伤模型)后,已转移所示单核细胞的老年WT小鼠的肝羟脯氨酸和天狼星红染色。比例尺为50μm。
图16:(A)气管内单次或多次滴注盐酸(酸)诱导肺损伤的实验方案。(B-C)酸滴注后,评估受损肺的呼吸功能(吸气量)的恢复和纤维化(羟脯氨酸)。每个点表示来自单个小鼠的数据。(D)用天狼星红染色法检测所示小鼠肺的胶原蛋白沉积。(E-H)在每次酸注射后,肺内皮细胞中EPCR、PAR1、NRP1和HIF2的表达。按先前方法分离肺内皮细胞,并通过定量PCR检测基因表达。每组N=6-8只小鼠。(I)免疫染色检测所示小鼠组的肺中EPCR和NRP1蛋白。比例尺=50μm。
图17:(A)内皮细胞特异性敲除Nrp1的小鼠的VE-钙黏蛋白+(VE-cadherin+)肺内皮细胞中EPCR和HIF2蛋白的表达。将Floxed Nrp1小鼠与表达他莫昔芬反应性(tamoxifen-responsive)内皮细胞特异性VE-钙黏蛋白-CreERT2(VE-cadherin-CreERT2)的小鼠杂交。用他莫昔芬处理小鼠,诱导内皮细胞中Nrp1的特异性缺失。以Nrp1内皮单链缺失(haplodeficiency)小鼠为对照。用免疫染色法检测,小鼠在酸损伤后所示时间内HIF2和EPCR的表达。(B)HIF2和EPCR在对照组小鼠和内皮特异性敲除Nrp1基因的小鼠肺内皮细胞中的转录表达。每组N=6只小鼠。(C)描述检测Nrp1抑制剂、活化蛋白C(APC)和Nrp1抑制剂和APC的联合(Nrp1抑制剂+APC)的治疗效果的策略的方案。(D)Nrp1抑制剂+APC治疗促进肺修复并绕过纤维化。在所示时间点检测小鼠肺中呼吸功能的恢复和羟脯氨酸的沉积。值得注意的是,Nrp1抑制剂+APC的治疗效果被EPCR阻断抗体1560减弱。(E)用Nrp1抑制剂、APC或APC+Nrp1抑制剂治疗后,酸损伤小鼠的肺功能(吸气量)的恢复。(F-G)Nrp1抑制剂+APC联合治疗,减少酸损伤小鼠肺中I型胶原沉积(F)和减少F4/80+巨噬细胞/单核细胞(G)的募集。同时,如磷酸化肌球蛋白轻链(phosphorylated myosin light chain,p-MLC)和VE-钙黏蛋白共染色显示,Nrp1抑制剂+APC降低了肺内皮细胞中Rho激活。比例尺=50μm。
图18:(A)分别通过重复注射CCl4和叶酸注射液诱导肝、肾纤维化。通过每3天腹腔注射8次CCl4诱导小鼠肝纤维化,通过叶酸诱导小鼠肾纤维化。(B)内皮细胞中EPCR抑制和Nrp1诱导的表达与肝、肾纤维化有关。(C)HIF2α抑制剂HY和APC的联合,阻断肝、肾纤维化。小鼠肝和肾纤维化模型中检测了靶向Nrp1(或HIF2α)和EPCR的“双管齐下”策略的治疗效果。用APC、Nrp1抑制剂EG、HIF2α抑制剂HY或EPCR中和抗体1560处理小鼠。(D)HIF2、EPCR、Nrp1在损伤和所述处理后所示时间点的肝脏和肾脏中的表达。EC标记物VE-钙黏蛋白和ERG也被染色以检测被测分子的血管分布。(E-F)在注射CCl4和叶酸及所示处理后,肝和肾功能的恢复。
图19:(A)ECs中EPCR的抑制和NRP1-HIF2α的激活,与肝脏和肾脏纤维化有关。EC标记物VE-钙黏蛋白被染色以确定被检测的分子的血管分布。在图19中,比例尺=50um。(B)在损伤和所述处理后,Nrp1iΔEC/iΔEC小鼠的肝脏和肾脏中HIF2α和EPCR的表达。(C-D)在第8次CCl4后的第20天,用所示处理的损伤的肝脏中肝脏羟脯氨酸量。每组N=8-9只小鼠。HY,HIF2α抑制剂,HIF-2α-IN-1(HY-19949)。(E)叶酸注射和所述处理后第100天的肾脏中血清肌酐量。每组N=8只小鼠。(F)叶酸注射后第100天,用所述处理的受损小鼠肾脏中纤维化面积的百分比。每组N=6只小鼠。(G)用所述处理的受损小鼠肝脏和肾脏中CXCR4+巨噬细胞的分布。CCl4和叶酸注射的所述处理后,肝脏和肾脏切片被CXCR4、F4/80和VE-钙黏蛋白染色。
实施例一:材料和方法
表1关键资源
动物养护和所用小鼠品系。Floxed神经纤毛蛋白1(Nrp1)小鼠和HIF2α(Hif2a)小鼠以及缺乏金属蛋白酶组织抑制剂1(Timp1)的小鼠、血小板因子-Cre(Pf4-Cre)小鼠获自杰克逊实验室。表达EC特异性Cdh5-(PAC)-CreERT2/VE-钙黏蛋白-CreERT2的小鼠由RalfAdams博士提供;该小鼠品系与floxed Nrp1和Hif2a小鼠杂交以产生Nrp1iΔEC/iΔEC、Hif2ai ΔEC/iΔEC和对照小鼠。腹腔内(i.p.)注射剂量为250mg/kg的他莫昔芬处理4周龄小鼠10天,并在第3次和第6次给药后中断一周(或以150mg/kg为剂量处理6天,并在第3次后中断3天)。定量聚合酶链反应(PCR)证实ECs中目标基因的删除。Nrp1iΔEC/iΔEC小鼠和Hif2aiΔEC/iΔEC小鼠以及年龄一致的同窝小鼠用于小鼠肺、肝和肾的损伤模型。Floxed Il1a小鼠由中国南京的集萃药康生物科技股份有限公司(GemPhamatech)用CRISPR/Cas9系统生成。共同注射Cas9mRNA、sgRNA和供体到受精卵中。sgRNA引导在内含子2-3和4-5中的Cas9核酸内切酶切割,并产生双链断裂。这种断裂通过同源重组导致loxP位点,并且外显子3和外显子4的区域被两侧插入loxP位点(floxed)。Il1a floxed小鼠与表达血小板因子4-Cre的小鼠交配。由此,血小板中两个loxP位点之间的序列被特异性删除,且Il1a基因被移码突变破坏。为了刺激EPCR信号,每3天对小鼠腹腔内注射(i.p.)0.1mg/kg APC。同时为了验证EPCR通路的特异性,通过每3天对小鼠腹腔内注射(i.p.)1.5mg/kg中和抗体1560阻断EPCR信号。为了抑制NRP1或HIF2α,每3天分别对小鼠腹腔内注射(i.p.)50mg/kg EG00229或25mg/kg HIF-2α-IN-1(HY-19949)。
本发明实施例中选择EG00229及其衍生物(EG00229(N2-[[3-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-2-thienyl]carbonyl]-L-arginine)和EG00229trifluoroacetate(N2-[[3-[(2,1,3-Benzothiadiazol-4-ylsulfonyl)amino]-2-thienyl]carbonyl]-L-arginine trifluoroacetate)和HIF-2α-IN-1(3-[[(3R)-4-(Difluoromethyl)-2,2-difluoro-3-hydroxy-1,1-dioxo-3H-1-benzothiophen-5-yl]oxy]-5-fluorobenzonitrile)的主要原因是上述抑制剂能够在体内有效抑制NRP1和HIF2α,从而可以用来证明抑制NRP1和HIF2α后所能产生的技术效果。但对本领域技术人员而言,本发明技术方案明显地并不局限于采用上述抑制剂。通过图1-3、6-11、13-14、17、19等敲除NRP1或HIF2α的实验结果可知,只要是能够有效抑制NRP1和HIF2α的物质(包括合适的小分子药物、抗体)或者可以通过对相应基因(例如,NRP1、HIF2α)进行编辑或敲除达到上述抑制效果的技术方案,都应在本发明的保护范围之内。同样地,本发明实施例中选择使用活化蛋白C(APC)的原因在于APC能够在体内有效刺激EPCR的信号并促进EPCR的表达。但通过EPCR中和抗体1560对EPCR信号进行阻断后,APC的有益效果被阻断的实验结果可以看出,本发明技术方案的关键是激活EPCR信号通路。因此,对本领域技术人员而言,任何能够刺激EPCR信号和/或促进EPCR的表达的技术方案,都应在本发明的保护范围之内,并不局限于采用APC。所有动物实验均按照四川大学的机构动物护理和使用委员会(Institutional AnimalCare and Use Committee)批准的实验方案进行。
小鼠肺再生与修复模型。为了检测小鼠肺泡再生和修复,调整了左肺PNX(参考文献19)和肺损伤(参考文献7)模型。用氯胺酮(ketamine)(100mg/kg)和甲苯噻嗪(xylazine)(10mg/kg)的混合物麻醉小鼠。当左肺叶被切除并在肺门周围缝合时进行PNX。从PNX后的20月龄(认定为老年)和3月龄(认定为年轻)的小鼠中纯化得到PCECs,并分离总RNA和按描述对其进行转录组分析。采用气管内注射2U/kg的博来霉素来诱导肺损伤。为了阻断EPCR信号,在PNX和Bleo注射后,向小鼠腹腔内注射1.5mg/kg的EPCR中和抗体1560(参考文献46)。还向PNX和PH后的年轻Nrp1iΔEC/iΔEC、Hif2aiΔEC/iΔEC和对照小鼠施用20μg/kg的小鼠PlGF或相同摩尔量的HGF和PDGF-BB(Peprotech)。另外,还通过反复的气管内盐酸注射模型来诱导肺损伤(参考文献76)。对麻醉后的小鼠进行经口气管滴注(Orotracheal instillation),并滴注20μl 0.1M盐酸(pH 1.0)的等渗溶液(iso-osmolar solution)。每次注射后,观察小鼠以确保其从麻醉中完全恢复,并使用外部热源保持其体温。恢复后,小鼠被转移到可以获得食物和水的通风的笼子里。在PNX和第1次酸注射后每3天,对小鼠施用0.1mg/kg APC、50mg/kg NRP1抑制剂、25mg/kg HIF2α抑制剂和1.5mg/kg 1560。在所述的时间点,如前所述(参考文献7)检测受处理的小鼠动脉血中的肺功能和氧张力。为了测量细胞增殖,在处死前1小时,向小鼠腹腔内注射100mg/kg的5-乙炔基-2'-脱氧尿苷(EDU),并且通过EDU细胞增殖试剂盒检测EDU掺入。在所有手术流程后,通过向小鼠腹腔内注射来补充1mL PBS。
免疫治疗诱导的肺炎的小鼠模型。在幅射后1个月,每4天、以10mg/kg的剂量向小鼠注射PD1抗体。监测小鼠的存活,并在幅射后3个月得到小鼠的肺组织。如前所述(参考文献19),收集BALF。为了检测荷瘤小鼠中免疫治疗诱导的肺炎,通过颈静脉血管、将200万个Lewis肺癌(LLC)细胞移植到老年Thpo-/-小鼠。为了检测血小板IL1α的作用,在注射LLC细胞后,将Il1a+/+或Il1a-/-血小板移植到受试小鼠中。小鼠同样接受PD1抗体和幅射处理。血小板移植后,在所示时间分析受试小鼠中肺纤维化、肿瘤负荷和动物存活率。
肺成纤维细胞和肝星状细胞的TIMP1处理。肺和肝成纤维细胞来自ScienceCell研究实验室(ScienceCell Research Laboratories),并如前所述培养(参考文献8)。肺和肝成纤维细胞用20ng/ml的TIMP1、10ng/ml的TGFβ1或20ng/ml的TIMP1和10ng/ml的TGFβ1处理。为了确定β1整合素在TIMP1介导的成纤维细胞的活化中的作用,通过shRNA使成纤维细胞中β1整合素沉默。处理后,回收肺和肝成纤维细胞用于通过免疫印迹分析Smad2磷酸化和SMA蛋白表达。Smad2磷酸化和SMA蛋白表达通过免疫印迹的光密度法定量。
小鼠肝脏再生与修复模型。通过PH诱导小鼠肝再生。对麻醉的小鼠进行中线剖腹手术,切除三个最前叶(右内侧叶、左内侧叶和左外侧叶)。打开腹部并暴露肝脏后,抬起将被切除的左叶。将5-0丝缝合线放置在所述叶下并定位到所述叶的起点。切断缝合处远端的打结叶,并对其他叶重复此流程以完成PH。手术切除70%的肝脏块(liver mass)后,封闭皮肤。如前所述(参考文献8),注射CCl4用于诱导肝损伤。CCl4在油(Sigma-Aldrich)中稀释以生成40%(0.64mg/ml)的浓度,并以1.6g/kg的剂量向小鼠腹腔注射。在PH和第1次CCl4注射后每3天,对小鼠注射0.1mg/kg APC、50mg/kg NRP1抑制剂、25mg/kg HIF2α抑制剂和1.5mg/kg 1560。PH后的所示时点,通过测量胆红素和AST的血清水平来评估肝功能的再生(参考文献8)。
小鼠肾脏再生与修复模型。采用描述的(参考文献72)小鼠肾I/R模型。麻醉小鼠后,通过在双肾上、30分钟的腹膜后途径(retroperitoneal approach)诱导缺血。假手术是在不诱导缺血下暴露肾脏进行的。为了产生肾纤维化,如前所述(参考文献74),以250mg/kg的剂量向小鼠单次腹腔注射叶酸。在肾I/R和叶酸注射后第40天后每3天,对小鼠注射0.1mg/kg APC、50mg/kg NRP1抑制剂、25mg/kg HIF2α抑制剂和1.5mg/kg 1560。在所示时间,通过苦味酸法测量血清肌酐浓度,并通过天狼星红和苏木精共染色分析组织形态和纤维化。
生长因子的注射与HDAC和DNMT抑制剂的治疗。3月龄(年轻)小鼠接受PNX、PH或肾脏I/R,并每三天注射20μg/kg的PlGF或等摩尔量的PDGF-BB、HGF、VEGF165或TGFβ1。3月龄Nrp1+/+、NrpiΔEC/iΔEC或Hif2aiΔEC/iΔEC小鼠同样用PlGF处理。为了检测PlGF和NRP1的调节,用10mg/kg的HDAC抑制剂VPA、0.5mg/kg的DNMT1抑制剂氮杂胞苷(AZA)或VPA和AZA的联合治疗(VPA+AZA)处理老年小鼠。通过免疫印迹法检测EPCR和NRP1蛋白在分离出的肺、肝和肾ECs中的表达,并通过ELISA法检测已匀浆的器官中PlGF量。
免疫荧光(IF)和形态计量分析。得到用于组织学分析的小鼠肺、肝和肾组织。封闭(5%驴血清/0.3%Triton X-100)10μm厚的组织冰冻切片并孵育在一抗中,4℃过夜:抗VE-钙黏蛋白多克隆抗体(pAb,2μg/ml,R&D Systems,MN)、抗SMA抗体(pAb,2μg/ml,Abcam,CA)、抗EPCR单克隆抗体(mAb 1560,5μg/ml)、抗平足蛋白(mAb,5μg/ml,R&D,MN)、抗水通道蛋白5(pAb,5μg/ml,Abcam,CA)、抗CD41(mAb,5μg/ml,BD Bioscience)。在荧光团缀合的(fluorophore-conjugated)二抗(2.5μg/ml,Jackson ImmunoResearch,PA)中孵育后,使用Prolong Gold封片剂(Invitrogen)与DAPI进行核染色。为了确定准备好的组织切片中免疫荧光染色信号,在五个不同的高倍视野上独立评估并定量每张载玻片中的荧光细胞,其代表单个标本的结果。
组织纤维化测定。在损伤后的所示时间测定肺、肝和肾的纤维化应答。组织在组织裂解缓冲液中均质。对获得的组织裂解物进行胶原蛋白I的免疫印迹。比较不同组之间胶原蛋白I的蛋白水平。对石蜡包埋的组织切片进行天狼星红和苏木精染色,来确定组织形态和胶原沉积及分布(参考文献8)。天狼星红阳性的纤维化的实质(parenchyma)是由每个切片的五个随机视野中确定并定量的。定量肝和肺中羟脯氨酸量,以确定纤维化的程度。
巨噬细胞/单核细胞的消耗(depletion)、分离和过继转移。用氯膦酸盐脂质体法选择性消耗小鼠的巨噬细胞/单核细胞(参考文献7)。PNX、PH或肾I/R的两天前及其后的每十天,将30μL氯膦酸盐包裹在脂质体(阴离子氯氟松,Clophosome-A)或空对照脂质体(Formu Max,Palo Alto,CA)中,静脉注射到小鼠体内,在慢性肺损伤期间消耗巨噬细胞/单核细胞。PNX、PH或肾I/R后,通过抗体包被的磁珠分离,分离出所示小鼠组织的巨噬细胞/单核细胞。通过定量PCR检测基因的表达。为了检测表达TIMP1的巨噬细胞/单核细胞在器官修复中的作用,从WT或Timp1-/-小鼠的骨髓中分离出单核细胞。PNX、PH、肾I/R或注射CCl4、博来霉素或叶酸的后1天,分别将3×106个WT和Timp1-/-单核细胞以静脉注射注入已消耗巨噬细胞的WT小鼠。在第一次移植后重复所述单核细胞的过继转移,直到处死受试小鼠。在接受WT或Timp1-/-单核细胞的不同组之间比较肺的、肝的、肾的功能与纤维化。通过天狼星红和苏木精染色检测胶原沉积和形态学特征。
小鼠血小板过继转移模型。采用先前描述(参考文献24)中的通过颈静脉注入血小板的策略。分离并浓缩血小板特异性删除Il1a(Il1aΔPlt/ΔPlt)小鼠的血小板以获得Il1a-/-血小板。野生型的血小板用作对照血小板。简而言之,用含有0.5mL ACD(12.5g/L柠檬酸钠、10.0g/L D-葡萄糖和6.85g/L柠檬酸)的注射器从麻醉的小鼠处采集血液。将收集的血液转移到含有150mM NaCl和20mM PIPES的5mL缓冲液中,并然后以100g离心15分钟。离心后,收集富含血小板的上清液。上清液再以1000g离心10分钟。将获得的血小板沉淀重悬并计数。在15分钟内,通过受试小鼠暴露的颈静脉注入2×109个血小板。
图像获得与分析。荧光图像记录在AxioVert LSM710共聚焦显微镜(蔡司)上。切片的分析记录在奥林巴斯BX51显微镜(Olympus America,NY)上。使用带有校准标准曲线的ImageJ软件进行免疫印迹图像的光密度分析。
定量和统计分析。用Prism 8软件包(GraphPad)进行计算。对于具有2个以上的组的数据集,采用单因素方差分析(one-way ANOVA)及随后的Tukey事后检验来确定显著性差异。实施例的统计学细节可以在图例中找到。所有数据均以平均值±平均值标准误差(SEM)表示。误差条(error bar)显示SEM,并且中心显示平均值。将p值<0.05视为统计学显著。
实施例二:老年小鼠肺中“再生向纤维化”的转变与“血小板-巨噬细胞”集落的形成以及内皮细胞的重编程有关
本发明实验人员用肺切除手术(PNX)来比较不同年龄的小鼠的肺泡再生和纤维化情况(图1A),包括肺功能的恢复、上皮结构和羟脯氨酸量(图1B-C,图8A-B)。与2、3以及6月龄小鼠相比,PNX后的20月龄小鼠显示肺泡再生的显著抑制和增加的纤维化。因此,本发明实验人员将20月龄小鼠定义为“老年”小鼠,并比较老年小鼠与2月龄(2-mon)或3月龄(3-mon)小鼠的再生能力。
血小板和巨噬细胞在器官修复中起着重要作用。基于此,本发明实验人员将PNX后的小鼠肺中的CD41+血小板和F4/80+巨噬细胞的沉积染色(图1D),发现PNX后的2月龄和3月龄小鼠肺中血小板的沉积极少;相反,老年小鼠肺中血小板与巨噬细胞联合,形成血管周围细胞集落(perivascular cellular rosettes)(图8C)。这些数据表明,血小板和巨噬细胞之间失调的相互作用可能有助于衰老的肺中“再生向纤维化”的转变。
在血管腔内侧的内皮细胞(ECs)形成抗炎症和抗血栓的界面,以维持器官的稳态。因此,本发明实验人员假设:ECs中的关键节点分子的重编程,活化血小板和巨噬细胞以促进纤维化。为了确定血管ECs在衰老相关的纤维化中的作用,本发明实验人员分离了PNX后2月龄和20月龄的小鼠的肺毛细血管内皮细胞(PCECs)。在转录谱(transcriptionprofiles)的基础上(图1E),比较了EPCR的表达,EPCR在ECs中是选择性表达的,神经纤毛蛋白1(NRP1)和HIF2α二者都是通过病理条件在ECs中诱导出(图8D)。相比于2月龄、3月龄与6月龄的小鼠,EPCR的表达在PNX后的老年小鼠的PCECs中更低。相反,NRP1和HIF2α的表达在PNX后的老年小鼠的PCECs中升高。因此,PNX后的衰老的肺似乎展示改变的血管分泌因子信号。
实施例三:老年肺中,正常化内皮细胞中的NRP1-HIF2α-EPCR回路减少“再生向纤维化”的转变
NRP1是多种细胞因子的共受体。为了探究NRP1在衰老相关的纤维化中的作用,本发明实验人员构建了内皮细胞中NRP1特异性缺乏的小鼠(Nrp1iΔEC/iΔEC)。Floxed NRP1小鼠与表达EC特异性的血管内皮细胞-钙黏蛋白(VE-cadherin)(Cdh5)-CreERT2的小鼠杂交。后代的他莫昔芬(Tamoxifen)处理,将后代的内皮细胞中NRP1删除(图8E)。老年Nrp1iΔEC/iΔEC小鼠接受PNX,并且3月龄(年轻)小鼠与老年Nrp1+/+小鼠作为对照。与老年对照小鼠相比,PNX后的老年Nrp1iΔEC/iΔEC小鼠的PCECs中显示更低的HIF2α表达和更高的EPCR水平(图1F,图8F)。经肺切除的老年肺中,内皮细胞NRP1的删除抑制了“血小板-巨噬细胞”集落的形成(图1G,图8G)。由于老年Nrp1iΔEC/iΔEC小鼠中EPCR表达上调,实验人员假定:老年Nrp1iΔEC/iΔEC小鼠中血管周围造血集落的形成的减少,依赖于EPCR的恢复。实际上,EPCR中和抗体1560阻断EPCR,恢复了老年Nrp1iΔEC/iΔEC小鼠的细胞集落的形成,这说明在EPCR的抑制以及随后血小板和巨噬细胞的活化中,NRP1的诱导的上位作用。
为了检验所述假设,本发明实验人员评估了老年Nrp1 iΔEC/iΔEC小鼠肺中再生的和纤维化的应答。与对照老年小鼠相比,PNX后的老年Nrp1iΔEC/iΔEC小鼠展示出更少的胶原沉积、增强的肺泡再生能力、降低的衰老和成纤维细胞活化、增加的II型肺泡上皮祖细胞增殖和更低数量的血管周围中性粒细胞(图1H,图8H-I)。抗体1560抑制了在老年Nrp1iΔEC/iΔEC小鼠中观察到的所述有益效果。这些数据表明,PNX后的老年Nrp1iΔEC/iΔEC小鼠中EPCR的正常化有利于再生而非纤维化(图1I)。
实施例四:衰老的肝和肾中重编程的造血-血管微环境将再生逆转成纤维化
评估不同年龄的小鼠的肝再生(图2A)。部分肝切除手术(PH)后,老年小鼠肝脏表现出纤维化样的症状(图9A)。PH后,在老年小鼠肝脏(而非3月龄小鼠)中还观察到“血小板-巨噬细胞”集落(图2B),在肝内皮细胞中NRP1、HIF2α和EPCR的表达有相似的变化(图2C-D)。与对照老年小鼠相比,PH后,老年Nrp1iΔEC/iΔEC小鼠展示出增加的肝细胞增殖和更低的纤维化,这与降低的“血小板-巨噬细胞”集落的形成有关(图2E-I,图9B)。PH后,注射1560抗体的老年Nrp1iΔEC/iΔEC小鼠逆转了其表型,这说明PH后的老年小鼠肝脏中NRP1依赖性EPCR的抑制,活化血小板和巨噬细胞。
通过缺血再灌注(I/R),诱导老年对照组和老年Nrp1iΔEC/iΔEC小鼠的急性肾损伤(图2J)。I/R后,老年小鼠的肾功能因纤维化而受损,其在老年小鼠(而非2月龄小鼠)肾中伴有“血小板-巨噬细胞”集落的形成(图2K)。在老年肾内皮细胞中,I/R相似地增加NRP1和HIF2α的表达并下调EPCR(图2L-N)。与老年对照组小鼠相比,老年Nrp1iΔEC/iΔEC小鼠显示,提高的肾脏修复与更高的细胞增殖程度、更少的纤维化和更少数量的“血小板-巨噬细胞”集落(图2O-R,图9C)。抗体1560逆转了肾I/R后的老年Nrp1iΔEC/iΔEC小鼠的表型,这说明Nrp1的删除的有益效果取决于EPCR。
实施例五:ECs中胎盘生长因子(PlGF)-NRP1轴的表观遗传上调,刺激HIF2α以抑制EPCR
PNX后,EPCR在年轻小鼠肺内皮细胞中被诱导出,而其在衰老的肺内皮细胞中被抑制(图9D)。内皮细胞中NRP1的删除,恢复了经肺切除的老年肺中EPCR的诱导。NRP1结合不同的配体,包括胎盘生长因子(PlGF)、肝细胞生长因子(HGF)、血小板源性生长因子BB(PDGF-BB)和转化生长因子β1(TGF-β1)。PlGF蛋白在PNX和PH后的衰老的肺和肝脏中上调(图9E)。向PNX后的年轻小鼠注射PlGF而非其他NRP1配体,抑制了EPCR表达并增强了HIF2α,这与老年小鼠的表型相似(图9F)。而所述PlGF的效果在Nrp1iΔEC/iΔEC小鼠中被抑制(图9G)。PNX后的老年肺中,内皮细胞中删除Hif2α(Hif2aiΔEC/iΔEC),相似地提高了EPCR的表达,并且注射PlGF没有抑制年轻Hif2aiΔEC/iΔEC小鼠的EPCR(图9G)。PH后的缺乏内皮细胞NRP1或者HIF2α的肝脏中,PlGF没有抑制EPCR的上调(图9H)。因此,PlGF-NRP1-Hif2α轴可能是造成损伤后的衰老器官中EPCR的抑制的原因。
因为表观遗传的改变有助于器官纤维化,本发明实验人员检测了组蛋白修饰和DNA甲基化对内皮细胞NRP1和PlGF表达的影响。PNX后,用组蛋白脱乙酰基酶(HDAC)抑制剂丙戊酸(VPA)、DNA甲基转移酶(DNMT)抑制剂5-氮杂胞苷(AZA)或VPA和AZA的联合治疗处理老年动物。对PNX后的老年小鼠的VPA的治疗,降低了肺内皮细胞中NRP1的表达,而其被AZA的联合治疗(VPA+AZA)进一步降低(图9I)。PH和肾脏I/R后,在老年小鼠中,VPA+AZA治疗抑制了肝和肾ECs中内皮细胞NRP1的上调(图9I)。VPA+AZA还抑制了PNX、PH或肾脏I/R后的老年肺、肝和肾中PlGF的上调(图9J)。因此,NRP1和PlGF的表达可能在衰老器官中受到表观遗传调控(图9K)。
实施例六:PCECs中NRP1-HIF2α轴刺激基质衍生因子1(SDF1)以募集促纤维化的巨噬细胞
PCECs产生旁分泌或血管分泌因子来调节肺泡的修复。因此,本发明实验人员分析了对照组和Nrp1iΔEC/iΔEC小鼠中肺内皮细胞和成纤维细胞中因子的表达(图10A-B)。Nrp1i ΔEC/iΔEC小鼠的PCECs中趋化因子SDF1显示受到最多的抑制。由于SDF1-CXCR4信号调节造血细胞功能和器官修复,本发明实验人员研究了在年轻和老年Sdf1报告小鼠(reportermice)中SDF1的表达模式(图3A)。PNX后,SDF1在老年小鼠(而不是年轻组)的PCECs中诱导出,并且ECs中Nrp1的删除抑制了SDF1表达(图3A)。
接下来,本发明实验人员检测在老年内皮细胞中HIF2α是否介导SDF1的产生。PNX后的老年Hif2aiΔEC/iΔEC小鼠,显示出较低水平的Sdf1、Par1、E-选择素和VCAM1(图3B)。由于SDF1、E-选择素和VCAM1促进内皮细胞-巨噬细胞串扰,实验人员对SDF1受体CXCR4和巨噬细胞标记物染色。与老年对照小鼠的肺相比,PNX后的老年Hif2aiΔEC/iΔEC小鼠和老年Nrp1i ΔEC/iΔEC小鼠肺中CXCR4+巨噬细胞的募集降低,这种现象被抗体1560逆转(图3C-D,图10C-D)。PNX后,老年Hif2aiΔEC/iΔEC小鼠肺泡上皮祖细胞的增殖增强,且抗体1560阻断了细胞增殖的增加(图3D,图10E)。PH和肾I/R后,老年Nrp1iΔEC/iΔEC小鼠显示出较低的纤维化(图10F),其伴有内皮细胞中SDF1和炎症基因的更低表达(图10G)。结果是,PH和肾I/R后,老年Hif2aiΔEC/iΔEC小鼠中血管周围CXCR4+巨噬细胞的富集减少(图10H)。因此,这些血管周围的CXCR4+巨噬细胞的募集,可能有助于老年器官中促纤维化的“血小板-巨噬细胞”集落的形成。
实施例七:CXCR4+巨噬细胞抑制老年器官的再生并引起纤维化
分离出PNX后的老年对照组和老年Hif2aiΔEC/iΔEC小鼠的肺巨噬细胞(图3E)。金属蛋白酶组织抑制剂1(TIMP1)在老年Hif2aiΔEC/iΔEC小鼠和对照组小鼠之间存在显著差异。接下来探究TIMP1的促纤维化作用。TIMP1被证明与参与活化成纤维细胞的整合素β1(β1integrin)相互作用。因此,本发明实验人员检验了TIMP1-整合素β1的相互作用对成纤维细胞活化的作用。用TIMP1孵育,增强了Smad2的磷酸化和平滑肌细胞肌动蛋白(SMA)的蛋白表达,而其通过用TGF-β1共处理被进一步增强(图3F-H)。通过沉默成纤维细胞中的整合素β1,减少了TIMP1引起的Smad2磷酸化和SMA上调。这些数据表明,TIMP1通过整合素β1刺激成纤维细胞的活化。
检测老年缺乏Timp1的小鼠(Timp1-/-)中TIMP1的促纤维化作用。PNX后,与对照组小鼠相比,老年Timp1-/-小鼠展示出降低的肺纤维化和增强的肺泡上皮覆盖的恢复(图4A)。与年轻器官相比,PNX、PH或肾脏I/R后的老年小鼠器官的巨噬细胞中,TIMP1的表达更高(图4B,图11A-C)。用CXCR4拮抗剂AMD3100处理,减少了小鼠老年器官的巨噬细胞中TIMP1的上调。这些发现提示,老年ECs中NRP1-HIF2α-EPCR通路的反常,刺激SDF1以募集表达TIMP1的CXCR4+巨噬细胞(图10I)。
为了揭示CXCR4+TIMP1高表达(CXCR4+TIMP1high)的巨噬细胞的作用,本发明实验人员采用了一种过继(adoptive)巨噬细胞转移方法(图4C)。Timp1-无效(Timp1-null)单核细胞的移植,促进了已肺切除的(pneumonectomized)老年小鼠的肺功能恢复并减少了胶原沉积(图4D-G)。PH和肾脏I/R后,向老年小鼠转移Timp1-/-单核细胞(而不是Timp1+/+),增强了实质功能的恢复并阻断了纤维化(图4H-J)。因此,老年器官的ECs中,NRP1-HIF2α-EPCR通路的重编程,诱导SDF1以募集促纤维化的CXCR4+TIMP1高表达的巨噬细胞,阻碍再生并刺激纤维化(图4K)。
实施例八:血小板产生白细胞介素1α(IL-1α)来激活促纤维化的TIMP1+巨噬细胞
血小板产生促炎细胞因子(如白介素)来与巨噬细胞相互作用。为了评估血小板IL-1α的作用,本发明实验人员构建了血小板特异性删除IL-1α的小鼠(Il1aΔPlt/ΔPlt)(图5A-B)。因为EPCR中和抗体1560诱导PNX后的年轻小鼠中纤维化样的表型(图12A-E),本发明实验人员使用抗体1560处理3月龄Il1aΔPlt/ΔPlt小鼠,以建立EPCR与血小板IL-1α之间的相关性。删除血小板中的Il1a,阻断了“血小板-巨噬细胞”集落的形成,并且降低了EPCR单克隆抗体处理的小鼠中促纤维化的TIMP1的肺部表达(图5C-G)。将Timp1缺乏的巨噬细胞/单核细胞移植到已注射抗体1560的年轻小鼠,同样阻断了肺纤维化(图12F-H)。因此,老年ECs中EPCR的抑制,导致血小板IL-1α的产生和促纤维化的TIMP1+巨噬细胞的活化,造成纤维化的表型。
使用血小板过继转移模型(参考文献52)(图5H)。向老年Thpo-/-小鼠注射野生型(Il1a+/+)或Il1a敲除(Il1a-/-)血小板,然后进行PNX、肝切除或肾I/R。评估受试小鼠的肺、肝、肾中TIMP1的表达和纤维化。与转移Il1a+/+血小板的老年小鼠相比,注射Il1a-/-血小板的老年小鼠的受试器官中,显示出降低的TIMP1表达和更少的胶原沉积(图5I-K)。这些数据提示,衰老器官中血小板IL-1α,促进促纤维化的“血小板-巨噬细胞”集落的形成和TIMP1的表达(图5L)。
实施例九:衰老器官中,正常化异常的内皮细胞-血小板串扰刺激再生而非纤维化
本发明实验人员使用博来霉素(Bleo)模型作为肺纤维化模型。用气管内注射博来霉素处理老年Nrp1iΔEC/iΔEC小鼠和对照组小鼠(图6A)。Bleo注射后,老年小鼠肺中PlGF上调(图6B),并且老年Nrp1iΔEC/iΔEC小鼠显示出比老年对照组小鼠更高的EPCR上调和HIF2α抑制(图6C),其与降低的纤维化、增强的肺泡再生的恢复、降低的细胞衰老和减少的血管周围CXCR4+巨噬细胞的募集有关(图6D-F,图13A-C)。通过EPCR中和抗体阻断了老年Nrp1iΔEC/iΔEC小鼠的表型提示,Bleo损伤后的老年小鼠中,ECs中重编程的NRP1-EPCR通路促进肺纤维化。
检测了所述Bleo模型中血小板和巨噬细胞对纤维化的作用。向Bleo损伤后的老年小鼠移植Il1a+/+和Il1a-/-血小板(图6G)。在损伤的受试肺中,移植Il1a-/-血小板减轻了造血集落的形成和TIMP1的表达(图6H)。抗体1560没有改变Il1a-/-血小板的效果。EPCR抗体对老年Nrp1iΔEC/iΔEC小鼠和老年Il1aΔPLT/ΔPLT小鼠中的差别效果提示,衰老的内皮细胞中的NRP1引起血小板IL-1α的产生。移植Timp1-/-单核细胞或缺乏Timp1的老年小鼠,显示出恢复的肺泡再生和减轻的纤维化(图6I-K,图13D-E)。因此,衰老的ECs中重编程的NRP1-HIF2α-EPCR信号活化IL-1α+血小板,并募集TIMP1高表达的巨噬细胞,以形成促纤维化的造血集落(图6L)。
免疫检查点阻断(如抗程序性细胞死亡蛋白1(PD1)抗体)在多种癌症类型中显示出显著的临床效益。然而,免疫治疗可能在部分患者中有潜在的风险,导致免疫治疗相关的不良事件(IrAEs)。肺炎是免疫检查点阻断治疗后常见的IrAEs之一。本发明实验人员检测了老年小鼠在PD1抗体处理后是否更易肺纤维化,尤其是联同放疗时。将老年小鼠和年轻小鼠暴露于胸部幅射1个月,来刺激免疫治疗诱发的肺炎(幅射后用或不用PD1抗体治疗)(图7A)。胸部幅射后的PD1抗体处理,在老年Hif2a+/+小鼠引起的肺纤维化程度高于3月龄Hif2a+/+小鼠或老年Hif2aiΔEC/iΔEC小鼠(图7B-C)。老年Hif2aiΔEC/iΔEC小鼠的死亡率和肺纤维化程度减少,EPCR抗体逆转这种现象(图7B-C)。移植Il1a-/-(而不是Il1a+/+)血小板的老年小鼠免于死亡和肺纤维化(图7D-F)。相反,EPCR抗体没有影响Il1a-/-血小板的这种保护作用,这提示检查点阻断后血小板IL-1α的促纤维化功能是EPCR的抑制的下游。因此,所述内皮细胞NRP1与血小板IL-1α的异常串扰,可能有助于老年患者的免疫治疗诱导的肺炎。
用荷瘤小鼠来检验EC-血小板异常串扰在免疫治疗诱导的肺炎中的促纤维化作用。注射lewis肺癌(LCC)细胞后,向老年小鼠移植Il1a+/+或者Il1a-/-血小板,然后进行PD1抗体处理(图7G)。与注射Il1a+/+血小板的小鼠相比,注射Il1a-/-血小板的受试小鼠,表现出降低的肿瘤细胞负荷和肺部纤维化(图7H-I)。与注入Il1a+/+血小板的受试小鼠相比,注入Il1a-/-血小板的受试小鼠存活率提高(图7J)。因此,在肺肿瘤的免疫治疗中,血小板产生的Il-1α可能引起肺纤维化并加剧死亡率。
年轻小鼠和老年小鼠接受注射肝毒素的四氯化碳(CCl4)或叶酸(参考文献2),以诱导肝纤维化或肾纤维化(图7K)。损伤后,老年受损的肝脏中PlGF表达上调(图7L)。老年对照组小鼠的EC中EPCR的抑制和HIF2α的诱导,在老年Nrp1iΔEC/iΔEC小鼠中恢复(图14A),其减轻了受损肝脏和肾脏的实质损伤和纤维化(图7M-N,图14B)。移植Il1a-/-血小板相似地降低了,受损的肝脏和肾脏中促纤维化的造血-血管集落的形成和TIMP1的表达(图7O,图14C)。在肝或肾损伤后,老年Timp1-/-小鼠或移植Timp1-/-单核细胞的小鼠的纤维化低于老年对照小鼠(图7P,图14D-E)。因此,在老年肺、肝和肾中,正常化血小板-巨噬细胞-血管细胞之间的异常串扰,使进行无纤维化的修复成为可能。
实施例十:
现有研究已经证明,肺内皮细胞形成微环境来启动肺再生和阻止纤维化(参考文献7、17、19、51)。本发明实验人员发现,在受损的肺、肝和肾中,内皮细胞NRP1的异常诱导,异常诱导转录因子HIF2并抑制EPCR。内皮微环境中EPCR保护性(protective)通路的破坏,导致受损肺、肝和肾的持续纤维化。NRP1的遗传切除(genetic ablation)或药理学阻断(pharmacological blockage)恢复了肺、肝和肾中受损的内皮细胞中EPCR的表达。
为了恢复内皮微环境受损的促再生功能,本发明实验人员采用了一种“双管齐下(two-hit)”策略,即诱导EPCR并注射其分子伴侣—活化蛋白C(activated protein C,APC)。NRP1/HIF2α抑制剂的联合施用,与APC协同作用,以达到:1)抑制内皮细胞中的Rho激活(Rho activation),2)减少炎性单核细胞的沉积,以及3)促进肺、肝和肾的无纤维化(fibrosis-free)修复。这实际上是通过上游通路增加了EPCR的表达,上游通路包括但不限于NRP1和HIF2α。实验数据表明,“微环境重编程疗法”对纤维化相关疾病的转化价值,包括临床应用的APC的给药和激活内皮微环境中其受体EPCR。通过本发明实验人员提出的“双管齐下”的技术方案,一方面通过活化EPCR并抑制NRP1和/或HIF2α来增加EPCR表达,加强其疗效,另一方面可以降低APC所需的使用剂量(与单独采用APC活化EPCR信号通路相比),从而减少其副反应的发生。
本实施例提出一个APC-EPCR通路在促进无纤维化器官修复中的作用的模型(图15)。该模型概要为:肺损伤后,肺内皮细胞上的EPCR有促进肺再生和避开肺纤维化的作用。持续性肺损伤,激活内皮细胞中的NRP1通路来上调HIF2,这抑制EPCR和上调PAR1。内皮微环境中EPCR通路的破坏,将再生反应逆转成肺纤维化。在治疗上,NRP1抑制剂或HIF2α抑制剂恢复EPCR的表达,其与活化蛋白C(APC)的施用共同作用以恢复保护性APC-EPCR通路。此外,通过小分子与重组蛋白来激活EPCR,实验数据表明,重编程促再生的EPCR+内皮微环境,可能激活肺、肝和肾中的无纤维化修复。
在反复的肺损伤模型(repeated lung injury model)中检测EC重编程对肺部纤维化的作用(参考文献76)。将盐酸(Acid)滴注到小鼠气管里面,每10天注射1次,一共注射5次(图16A)。注射3次酸后,受损的肺恢复了气体交换功能。相比之下,气体交换功能的恢复在第5次注射后被抑制(图16B)。被抑制的肺部功能恢复与持续的纤维化有关(图16C-D)。显著地,在PCECs中,EPCR的诱导与肺部功能的恢复有关;当纤维化发生时,NRP1、HIF2α和PAR1在PCECs中上调(图16E-I)。上述结果表明,小鼠反复吸入盐酸后,内皮细胞中EPCR的抑制和NRP1的诱导与肺纤维化有关。在第5次酸注射后,与对照组小鼠相比,Nrp1iΔEC/iΔEC小鼠的PCECs中显示较高的EPCR表达和较低的HIF2α和PAR1表达(图17A-B)。因此,反复的肺损伤导致PCECs中NRP1-HIF2α-EPCR信号的重编程。
随后检测,通过注射APC和EG(APC+EG)来靶向重编程的PCECs是否会恢复肺部修复并减少纤维化(图17C)。在反复酸损伤后的所有检测的组中,APC+EG最有效地恢复了肺部功能并减少了纤维化(图17D-G)。在反复肺损伤后,经APC+EG治疗的PCECs中血管周围巨噬细胞的募集被抑制(图17F-G)。先前证明,APC抑制ECs中的Rho通路的激活。的确,在APC+EG治疗后,PCECs的磷酸化肌球蛋白轻链(phosphorylated myosin light chain,p-MLC)被阻断(图17F-G)。因此,双管齐下策略,即共同注射APC和NRP1抑制剂,刺激长期受损的PCECs中正常化的EPCR信号并减少促纤维化的血管周围巨噬细胞的募集,即刺激PCECs中正常化的EPCR通路,促进无纤维化的(fibrosis-free)肺修复。
然后在小鼠肝脏和肾脏长期损伤(chronic injury)模型中检测了上述双管齐下策略的治疗效果(图18A)。小鼠被反复注射肝脏毒素四氯化碳(CCl4)或注射叶酸(参考文献77)。在第1次注射CCl4后或注射叶酸后第10天,EPCR在ECs中被诱导出。相比之下,在第8次CCl4注射后和叶酸注射后100天,ECs中EPCR的表达被阻断且NRP1和HIF2α被刺激出(图19A)。用APC治疗Nrp1iΔEC/iΔEC小鼠,抑制了HIF2α的诱导,增强了长期受损的肝脏和肾脏ECs中EPCR的表达(图19B),表明EPCR在肝脏和肾脏修复中具有促进再生的功能。
然后用APC、EG或HIF2α抑制剂HIF-2α-IN-1(HY-19949)处理小鼠,并于第8次CCl4注射后或叶酸注射100天后进行评估。APC+EG抑制了肝脏和肾脏ECs中Sdf1、Par1、Vcam1和Hif2a的表达(图18B),并减少了肝脏的纤维化(图19C)。共同注射APC和HY-19949(APC+HY)阻断了血管周围CXCR4+巨噬细胞的募集,并抑制了受损肝脏和肾脏的实质损伤和纤维化(图18C,图19D-G)。此外,在纤维化的肝脏和肾脏损伤后,APC+EG阻断了
SDF1报告小鼠ECs中SDF1的表达(图18D)并增强了实质功能的恢复(图18E-F)。所有这些有益效果都被EPCR中和抗体1560的注射而阻断。因此,通过双管齐下策略(APC+NRP1/HIF2α),靶向重编程的NRP1-HIF2α-EPCR(也可以理解为,靶向肝脏和肾脏中重编程的ECs)使长期损伤的肝脏和肾脏实现无纤维化修复。上述实验表明,在血管微环境中激活正常化的EPCR信号,促进多种器官的无纤维化修复。需要强调的是,通过图17-19等阻断EPCR信号的实验结果可知,EPCR中和抗体1560(阻断EPCR信号的一种方式)减弱了APC应达到的有益技术效果。因此,活化EPCR信号通路是本发明技术方案的关键,对本领域技术人员而言,任何能够刺激EPCR信号和/或促进EPCR的表达的物质都应在本发明的保护范围之内,并不局限于采用APC。
总结
衰老的器官在损伤后易发生纤维化。在上述实施例中,本发明实验人员展示了血小板、巨噬细胞和血管内皮细胞之间与衰老相关的重编程的串扰,导致再生能力的缺失以及纤维化。血小板释放的IL-1α可刺激巨噬细胞的促纤维化功能。血流动力学、血糖和血脂的变化都导致IL-1α的释放。本发明研究结果提示,在受损老年器官中,衰老的ECs中血小板的活化和IL-1α的产生,至少部分归因于抗血栓的EPCR信号的抑制。因此,血管微环境中多功能的EPCR信号的缺失,可能是衰老相关的再生向纤维化转变的因素之一。EPCR在调节血栓形成、炎症和发育方面具有多效性功能。本发明数据表明,衰老的ECs中EPCR的诱导受到异常激活的NRP1-HIF2α通路的抑制。
血小板可以被分级活化以发挥不同的病理生理学效果。在肺切除或肝切除后,活化的血小板提供各种介体以启动肺和肝的再生。本发明实验人员以前使用肺切除术和肝切除术证明SDF1在促进肺和肝再生的功能。肺切除和肝切除模型的重要特征之一是,这些流程诱导生理学再生,其不参与正常年轻小鼠中显著的炎症和血栓形成。在生理学再生中,SDF1可能主要刺激其在血管内皮或上皮细胞/肝细胞的受体,促进上皮和内皮细胞的增殖。因此,在肺切除或肝切除后的年轻小鼠中,SDF1引起血管和上皮/肝细胞的再生。相比之下,EPCR受到抑制的衰老动物中,肺切除或肝切除流程与血栓和炎症有关。在这些条件下,SDF1增强产生促纤维化的TIMP1的CXCR4+巨噬细胞的募集和积聚。因此,在没有明显的炎症和血栓的情况下,SDF1可能主要作用于上皮细胞和内皮细胞来促进再生。在炎症和血栓水平较高的情况下,SDF1活化如巨噬细胞等炎症细胞中的CXCR4,产生如TIMP1等促纤维化的因子。
本发明揭示的细胞机制可能有助于使免疫细胞的异常激活正常化,并在临床情况下避开免疫细胞的促纤维化的功能。例如,所述机制可用来应对IrAEs。本发明发现,在用PD1阻断处理的老年小鼠中,靶向血小板IL-1α或内皮细胞HIF2α,提高了老年小鼠的生存率并减轻了肺纤维化。这些数据提示,肺炎和纤维化可能是免疫治疗(尤其是联同化疗或放疗)后老年患者的危险因素。
本发明表明,衰老器官中衰老相关的异常重编程血小板、巨噬细胞和血管细胞之间的串扰,以将再生逆转成纤维化。而本发明揭示的导致器官纤维化的机制,并非仅是衰老特异性的。正常化促纤维化的造血-血管微环境,可能有助于在病理条件下恢复再生能力。在重编程的ECs中,遗传学和药理学靶向Neuropilin-1或HIF2α,使EPCR信号正常化,这与EPCR活化剂(agonist)活化蛋白C(APC)协同作用,抑制衰老的和长期受损的器官中促纤维化的巨噬细胞的募集。失调的血管和免疫微环境的正常化,可能在一定程度上恢复衰老的或纤维化的器官的再生能力。
上面结合附图对本发明的实施例进行了描述,但是本发明并不局限于上述的具体实施方式,上述的具体实施方式仅仅是示意性的,而不是限制性的,本领域的普通技术人员在本发明的启示下,在不脱离本发明宗旨和权利要求所保护的范围情况下,还可做出很多形式,这些均属于本发明的保护之内。
参考文献
1.Organotypic vasculature:From descriptive heterogeneity tofunctional pathophysiology.2017,Science 357.
2.Methylation determines fibroblast activation and fibrogenesis inthe kidney.2010,Nature medicine 16,544-550.
3.A vascular niche and a VEGF-Nrp1 loop regulate the initiation andstemness of skin tumours.2011,Nature 478,399-403.
4.Platelets:covert regulators of lymphatic development.2010,Arteriosclerosis,thrombosis,and vascular biology 30,2368-2371.
5.Vascular endothelial growth factor-B acts as a coronary growthfactor in transgenic rats without inducing angiogenesis,vascular leak,orinflammation.2010,Circulation 122,1725-1733.
6.Angiogenesis and vascular functions in modulation of obesity,adipose metabolism,and insulin sensitivity.2013,Cell Metab 18,478-489.
7.Targeting of the pulmonary capillary vascular niche promotes lungalveolar repair and ameliorates fibrosis.2016,Nature medicine 22,154-162.
8.Targeting the vascular and perivascular niches as a regenerativetherapy for lung and liver fibrosis.2017,Science translational medicine 9.
9.Molecular mechanisms and clinical applications ofangiogenesis.2011,Nature 473,298-307.
10.Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1signaling blockade inhibits angiogenesis and restores antitumorimmunity.2013,Cancer cell 24,695-709.
11.Activated protein C blocks p53-mediated apoptosis in ischemichuman brain endothelium and is neuroprotective.2003,Nat Med 9,338-342.
12.Targeting HIF2 in Clear Cell Renal Cell Carcinoma.2016,Cold SpringHarbor symposia on quantitative biology 81,113-121.
13.Role of endothelial cell metabolism in vessel sprouting.2013,CellMetab 18,634-647.
14.Macrophage regulation of tumor responses to anticancertherapies.2013,Cancer Cell 23,277-286.
15.Alveolar progenitor and stem cells in lung development,renewal andcancer.2014,Nature.
16.Translational strategies and challenges in regenerativemedicine.2014,Nature medicine 20,814-821.
17.Divergent angiocrine signals from vascular niche balance liverregeneration and fibrosis.2014,Nature 505,97-102.
18.Inductive angiocrine signals from sinusoidal endothelium arerequired for liver regeneration.2010,Nature 468,310-315.
19.Endothelial-derived angiocrine signals induce and sustainregenerative lung alveolarization.2011,Cell 147,539-553.
20.Regulation of hypoxia-inducible factor 2alpha signaling by thestress-responsive deacetylase sirtuin 1.2009,Science 324,1289-1293.
21.Distinct mechanisms regulate TIMP-1expression at different stagesof phorbol ester-mediateddifferentiation of U937 cells.1997,Biochemistry 36,2492-2500.
22.Molecular circuits in thrombosis and inflammation.2013,ThrombHaemost 109,416-420.
23.Therapy for fibrotic diseases:nearing the starting line.2013,Science translational medicine 5,167sr161.
24.Infusion of mature megakaryocytes into mice yields functionalplatelets.2010,The Journal of clinical investigation 120,3917-3922.
25.Migrating Platelets Are Mechano-scavengers that Collect and BundleBacteria.2017,Cell 171,1368-1382.
26.Activated PMN Exosomes:Pathogenic Entities Causing MatrixDestruction and Disease in the Lung.2019,Cell 176,113-126.
27.Macrophage heterogeneity in tissues:phenotypic diversity andfunctions.2014,Immunol Rev 262,36-55.
28.Semaphorin 3E and plexin-D1 control vascular pattern independentlyof neuropilins.2005,Science 307,265-268.
29.PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells.2015,Nat Med 21,1307-1317.
30.Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2redox imbalance.2014,Science translational medicine 6,231ra247.
31.Targeting of alphav integrin identifies a core molecular pathwaythat regulates fibrosis in several organs.2013,Nature medicine 19,1617-1624.
32.Heterotypic interactions enabled by polarized neutrophilmicrodomains mediate thromboinflammatory injury.2009,Nature medicine 15,384-391.
33.Repair and regeneration of the respiratory system:complexity,plasticity,and mechanisms of lung stem cell function.2014,Cell stem cell 15,123-138.
34.Activated protein C protects against diabetic nephropathy byinhibiting endothelial and podocyte apoptosis.2007,Nat Med 13,1349-1358.
35.Cytokine-mediated deployment of SDF-1 induces revascularizationthrough recruitment of CXCR4+hemangiocytes.2006,Nature medicine 12,557-567.
36.Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytesimproves antiangiogenic therapy in colorectal cancer.2017,Proceedings of theNational Academy of Sciences of the United States of America 114,10455-10460.
37.Vascular and neurogenic rejuvenation of the aging mouse brain byyoung systemic factors.2014,Science 344,630-634.
38.HIF1alpha and HIF2alpha:sibling rivalry in hypoxic tumour growthand progression.2011,Nat Rev Cancer 12,9-22.
39.Lung regeneration:mechanisms,applications and emerging stem cellpopulations.2014,Nature medicine 20,822-832.
40.Perivascular Gli1+progenitors are key contributors to injury-induced organ fibrosis.2015,Cell stem cell 16,51-66.
41.Age-dependent modulation of vascular niches for haematopoieticstem cells.2015,Nature 532,380-384.
42.Aggravation of viral hepatitis by platelet-derived serotonin.2008,Nature medicine 14,756-761.
43.Recruited Monocytes and Type 2 Immunity Promote Lung Regenerationfollowing Pneumonectomy.2017,Cell Stem Cell 21,120-134 e127.
44.The lung is a site of platelet biogenesis and a reservoir forhaematopoietic progenitors.2017,Nature 544,105-109.
45.Platelet-derived serotonin mediates liver regeneration.2006,Science 312,104-107.
46.Overexpressing endothelial cell protein C receptor alters thehemostatic balance and protects mice from endotoxin.2005,J Thromb Haemost 3,1351-1359.
47.WNT7b mediates macrophage-induced programmed cell death inpatterning of the vasculature.2005,Nature 437,417-421.
48.Platelet-macrophage partnership in innate immunity andinflammation.2013,Nature immunology 14,768-770.
49.Peptidylarginine deiminase 4 promotes age-related organfibrosis.2017,The Journal of experimental medicine 214,439-458.
50.Pulmonary fibrosis:patterns and perpetrators.2012,The Journal ofclinical investigation 122,2756-2762.
51.Platelet-derived SDF-1 primes the pulmonary capillary vascularniche to drive lung alveolar regeneration.2015,Nature cell biology 17,123-136.
52.Functional significance of the platelet immune receptors GPVI andCLEC-2.2019,The Journal of clinicalinvestigation 129,12-23.
53.Endothelium-microenvironment interactions in the developing embryoand in the adult.2007,Developmental cell 12,181-194.
54.Activation of endothelial cell protease activated receptor 1 bythe protein C pathway.2002,Science 296,1880-1882.
55.A Paradigm Shift in Cancer Immunotherapy:From Enhancement toNormalization.2018,Cell 175,313-326.56.Platelet-derived nucleotides promotetumor-cell transendothelial migration and metastasis via P2Y2receptor.2013,Cancer cell 24,130-137.
57.Restoring systemic GDF11 levels reverses age-related dysfunctionin mouse skeletal muscle.2014,Science 344,649-652.
58.Targeting placental growth factor/neuropilin 1 pathway inhibitsgrowth and spread of medulloblastoma.2013,Cell 152,1065-1076.
59.VEGF modulates erythropoiesis through regulation of adult hepaticerythropoietin synthesis.2006,Nature medicine 12,793-800.
60.Dedifferentiation of committed epithelial cells into stem cells invivo.2013,Nature 503,218-223.
61.Timp1 interacts with beta-1 integrin and CD63 along melanomagenesis and confers anoikis resistance by activating PI3-K signaling pathwayindependently of Akt phosphorylation.2013,Molecular cancer 12,22.
62.Lineage-negative progenitors mobilize to regenerate lungepithelium after major injury.2015,Nature 517,621-625.
63.Regenerative activity of the lung after epithelial injury.2013,Biochimica et biophysica acta 1832,922-930.64.Hepatocyte TAZ/WWTR1 PromotesInflammation and Fibrosis in Nonalcoholic Steatohepatitis.2016,Cell Metab 24,848-862.
65.Ephrin-B2 controls VEGF-induced angiogenesis andlymphangiogenesis.2010,Nature 465,483-486.
66.Endothelial expression of hypoxia-inducible factor 1 protects themurine heart and aorta from pressure overload by suppression of TGF-betasignaling.2012,Proceedings of the National Academy of Sciences of the UnitedStates of America 109,E841-850.
67.Hierarchical organization of the hemostatic response topenetrating injuries in the mouse macrovasculature.2017,Journal of thrombosisand haemostasis:JTH 15,526-537.
68.FOXO1 couples metabolic activity and growth state in the vascularendothelium.2016,Nature 529,216-220.
69.Nucleation of platelets with blood-borne pathogens on Kupffercells precedes other innate immunity and contributes to bacterialclearance.2013,Nature immunology 14,785-792.
70.Macrophage biology in development,homeostasis and disease.2013,Nature496,445-455.
71.Mechanisms of fibrosis:therapeutic translation for fibroticdisease.2012,Nature medicine 18,1028-1040.
72.Epithelial cell cycle arrest in G2/M mediates kidney fibrosisafter injury.2010,Nature medicine 16,535-543,531p following 143.
73.Endothelial-to-mesenchymal transition contributes to cardiacfibrosis.2007,Nature medicine 13,952-961.
74.BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymaltransition and reverses chronic renal injury.2003,Nat Med 9,964-968.
75.The metabolic regulation of aging.2015,Nature medicine 21,1416-1423.
76.Neutrophils promote alveolar epithelial regeneration by enhancingtype II pneumocyte proliferation in a model of acid-induced acute lunginjury.American journal of physiology.2016,Lung cellular and molecularphysiology 311,L1062-L1075.
77.Methylation determines fibroblast activation and fibrogenesis inthe kidney.2010,Nat Med 16,544-550.
Claims (11)
1.EPCR通路活化剂在制备抗纤维化剂中的应用,所述EPCR通路活化剂促进EPCR通路的活性。
2.如权利要求1所述的应用,其特征在于,所述EPCR通路活化剂包括活化蛋白C。
3.如权利要求1所述的应用,其特征在于,所述纤维化包括器官纤维化,所述器官纤维化可选地为与衰老相关的器官纤维化。
4.如权利要求3所述的应用,其特征在于,所述器官纤维化包括肝纤维化、肾纤维化、肺纤维化和心纤维化中的一种或多种,所述肺纤维化可选地为免疫治疗相关肺炎引起的纤维化。
5.如权利要求1所述的应用,其特征在于,所述应用包括减轻受损器官的纤维化程度和/或促进受损器官的再生能力,所述再生能力包括细胞增殖能力、组织修复能力和功能恢复能力中的一种或多种。
6.如权利要求1所述的应用,其特征在于,所述应用包括减轻血小板-巨噬细胞集落的形成;和/或降低血小板IL-1α、SDF1、TIMP1中的一种或多种的表达。
7.如权利要求1-6任一项所述的应用,其特征在于,所述EPCR通路活化剂用于与NRP1抑制剂和/或HIF2α抑制剂联用制备所述抗纤维化剂,所述NRP1抑制剂和/或HIF2α抑制剂用于促进EPCR的表达。
8.如权利要求7所述的应用,其特征在于,所述NRP1抑制剂包括抑制NRP1蛋白活性的物质、降解NRP1蛋白活性的物质和降低NRP1蛋白水平的基因工具中的一种或多种;所述HIF2α抑制剂包括抑制HIF2α蛋白活性的物质、降解HIF2α蛋白活性的物质和降低HIF2α蛋白水平的基因工具中的一种或多种。
9.如权利要求7所述的应用,其特征在于,所述NRP1抑制剂包括EG00229或其衍生物;所述HIF2α抑制剂包括HIF-2α-IN-1或其衍生物。
10.如权利要求8所述的应用,其特征在于,所述抑制NRP1蛋白活性的物质包括小分子药物和/或抗体;所述抑制HIF2α蛋白活性的物质包括小分子药物和/或抗体。
11.如权利要求8所述的应用,其特征在于,所述降低NRP1蛋白水平的基因工具包括RNA干扰、microRNA、基因编辑和基因敲除中的一种或多种;所述降低HIF2α蛋白水平的基因工具包括RNA干扰、microRNA、基因编辑和基因敲除中的一种或多种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311576123.5A CN117414430A (zh) | 2020-12-16 | 2021-12-08 | Epcr通路活化剂在制备抗纤维化剂中的应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020114826031 | 2020-12-16 | ||
CN202011482603 | 2020-12-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311576123.5A Division CN117414430A (zh) | 2020-12-16 | 2021-12-08 | Epcr通路活化剂在制备抗纤维化剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113952456A true CN113952456A (zh) | 2022-01-21 |
CN113952456B CN113952456B (zh) | 2023-12-15 |
Family
ID=79473093
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111490103.7A Active CN114452389B (zh) | 2020-12-16 | 2021-12-08 | 一种抗纤维化药物组合物及其应用 |
CN202311576123.5A Pending CN117414430A (zh) | 2020-12-16 | 2021-12-08 | Epcr通路活化剂在制备抗纤维化剂中的应用 |
CN202111512532.XA Active CN113952456B (zh) | 2020-12-16 | 2021-12-08 | Epcr通路活化剂在制备抗纤维化剂中的应用 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111490103.7A Active CN114452389B (zh) | 2020-12-16 | 2021-12-08 | 一种抗纤维化药物组合物及其应用 |
CN202311576123.5A Pending CN117414430A (zh) | 2020-12-16 | 2021-12-08 | Epcr通路活化剂在制备抗纤维化剂中的应用 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP4282424A1 (zh) |
CN (3) | CN114452389B (zh) |
WO (1) | WO2022127654A1 (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0619611D0 (en) * | 2006-10-04 | 2006-11-15 | Ark Therapeutics Ltd | Compounds and their use |
CA2931085C (en) * | 2013-12-16 | 2021-10-19 | Peloton Therapeutics, Inc. | Cyclic sulfone and sulfoximine analogs and uses thereof |
-
2021
- 2021-12-08 WO PCT/CN2021/136240 patent/WO2022127654A1/zh unknown
- 2021-12-08 CN CN202111490103.7A patent/CN114452389B/zh active Active
- 2021-12-08 CN CN202311576123.5A patent/CN117414430A/zh active Pending
- 2021-12-08 EP EP21905583.7A patent/EP4282424A1/en active Pending
- 2021-12-08 CN CN202111512532.XA patent/CN113952456B/zh active Active
Non-Patent Citations (4)
Title |
---|
BRYAN L. COPPLE 等: ""Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic hepatocytes"", 《LIVER INTERNATIONAL》 * |
LARA MATILLA 等: ""Soluble St2 Induces Cardiac Fibroblast Activation and Collagen Synthesis via Neuropilin-1"", 《CELLS》 * |
MRYANDA J. SOPEL等: ""Treatment with Activated Protein C (aPC) Is Protective during the Development of Myocardial Fibrosis: An Angiotensin II Infusion Model in Mice"", 《PLOS ONE》 * |
SHINO SHIMIZU 等: ""Activated Protein C Inhibits the Expression of Platelet-derived Growth Factor in the Lung"", 《AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114452389A (zh) | 2022-05-10 |
CN113952456B (zh) | 2023-12-15 |
CN114452389B (zh) | 2023-08-25 |
EP4282424A1 (en) | 2023-11-29 |
CN117414430A (zh) | 2024-01-19 |
WO2022127654A1 (zh) | 2022-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Klein et al. | Mesenchymal stem cell therapy protects lungs from radiation-induced endothelial cell loss by restoring superoxide dismutase 1 expression | |
Wu et al. | Bone marrow‐derived mesenchymal stem cell attenuates skin fibrosis development in mice | |
Chen et al. | Aging reprograms the hematopoietic-vascular niche to impede regeneration and promote fibrosis | |
Chen et al. | Inhibition of Wnt/β-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-β1 and FGF-2 | |
Zemp et al. | Treating brain tumor–initiating cells using a combination of myxoma virus and rapamycin | |
Zhang et al. | MicroRNA‐182 exacerbates blood‐brain barrier (BBB) disruption by downregulating the mTOR/FOXO1 pathway in cerebral ischemia | |
US11965034B2 (en) | Antifibrotic activity of CD47 blockade in the liver | |
JP2009528977A (ja) | 慢性線維形成性疾患を治療するための物質および方法 | |
Xu et al. | Bmal1 downregulation worsens critical limb ischemia by promoting inflammation and impairing angiogenesis | |
Racanelli et al. | Autophagy in chronic lung disease | |
CN115068612B (zh) | Drd2抑制剂在制备治疗与肝脏纤维化有关的疾病的药物中的应用 | |
Zhang et al. | Myeloid‐specific blockade of Notch signaling alleviates murine pulmonary fibrosis through regulating monocyte‐derived Ly6cloMHCIIhi alveolar macrophages recruitment and TGF‐β secretion | |
Chang et al. | Bone marrow transplantation rescues intestinal mucosa after whole body radiation via paracrine mechanisms | |
Nie et al. | NFATc3 promotes pulmonary inflammation and fibrosis by regulating production of CCL2 and CXCL2 in macrophages | |
US10400035B2 (en) | Methods of protecting a solid organ transplant tissue with angiopoietin-2 antibodies | |
WO2017041114A2 (en) | Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof | |
CN113952456B (zh) | Epcr通路活化剂在制备抗纤维化剂中的应用 | |
US20090291087A1 (en) | Modulating angiogenesis | |
Ravindran et al. | Broad‐spectrum chemokine inhibition blocks inflammation‐induced angiogenesis, but preserves ischemia‐driven angiogenesis | |
CN114306371B (zh) | Nron的表达促进剂在制备动脉粥样硬化斑块动物模型中的用途 | |
US20130078224A1 (en) | Induction/monitoring of arteriogenesis using sdf1 and pdgfb or inhibition of phd2 | |
Meng et al. | Mesenchymal Stem Cells Attenuates Hirschsprung diseases-Associated Enterocolitis by Reducing M1 Macrophages Infiltration via COX-2 Dependent Mechanism | |
Volpe | miR-200c prevents and reverts Lung fibrosis by down regulating Flt1 and promoting lung regeneration | |
US20110280874A1 (en) | Modulating angiogenesis | |
Zhu et al. | IL20Rb aggravates pulmonary fibrosis through enhancing bone marrow derived profibrotic macrophage activation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |